

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
[Immuno-Oncology
Summit.com](http://Immuno-OncologySummit.com)



250 First Avenue
Needham, MA 02494
www.healthtech.com



CAMBRIDGE HEALTHTECH INSTITUTE'S 4TH ANNUAL

Immuno-Oncology SUMMIT

Collaborating to Develop the Next Generation of Targeted Immunotherapy

AUGUST 29-SEPTEMBER 2, 2016

MARRIOTT LONG WHARF
BOSTON, MA

REGISTER BY JUNE 10 AND SAVE UP TO \$350!



Conference Programs



Immunomodulatory
Antibodies



Combination
Immunotherapy



Adoptive T Cell
Therapy



Oncolytic Virus
Immunotherapy



Personalized
Immunotherapy



Biomarkers
for Immuno-Oncology



Training Seminar:
Immunology for Drug
Discovery Scientists




Preclinical &
Translational
Immuno-Oncology



Clinical Trials
for Cancer
Immunotherapy

Plenary Keynote Speakers



Matthew J. Goldstein

M.D., Ph.D., Director,
Translational Medicine,
Neon Therapeutics Inc.



Michael Rosenzweig

Ph.D., Executive Director,
Biology-Discovery, IMR Early
Discovery, Merck Research
Laboratories



Morganna Freeman

D.O., Associate Director,
Melanoma & Cutaneous Oncology
Program, The Angeles Clinic and
Research Institute

CORPORATE SPONSORS

CORPORATE SUPPORT SPONSORS



ABZENA
Enabling better biopharmaceuticals

PGD



**Systems
Imagination**

intellicyt

**PRECISION
FOR MEDICINE**
THE FUTURE OF MEDICINE IS PRECISION

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
[Immuno-Oncology
Summit.com](http://Immuno-Oncology
Summit.com)



250 First Avenue
Needham, MA 02494
www.healthtech.com



Immuno-Oncology SUMMIT

MEET THOUGHT LEADERS IN CANCER IMMUNOTHERAPY AT THE PREMIER ANNUAL IO EVENT

As our understanding of tumor immunology has advanced, immuno-oncology has made unprecedented progress in improving the outcomes for cancer patients. Still, with the field in its infancy, the full curative potential of IO has yet to be realized. CHI's 4th Annual Immuno-Oncology Summit has been designed to support a coordinated effort by industry players to bring commercial immunotherapies and immunotherapy

combinations through clinical development and into the market. This weeklong, nine-meeting set will include topics ranging from early discovery through clinical development as well as emerging areas such as oncolytic virus immunotherapy. Overall, this event will provide a focused look at how researchers are applying new science and technology in the development of the next generation of effective and safe immunotherapies.

Who Will Attend?

Scientific leaders, C-level executives, professors, site directors and researchers from pharma, biotech, academia, and government working in the areas of immuno-oncology, immunotherapy, antibody and protein engineering, biomarker discovery, immunology, cell and gene therapy, and preclinical and clinical development.

CONFERENCE AT-A-GLANCE

MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY
 Immunomodulatory Antibodies		 Combination Immunotherapy	 Adoptive T Cell Therapy	
 Oncolytic Virus Immunotherapy		 Personalized Immunotherapy	 Biomarkers for Immuno-Oncology	
 Training Seminar: Immunology for Drug Discovery Scientists		 Preclinical & Translational Immuno-Oncology	 Clinical Trials for Cancer Immunotherapy	

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

Plenary Keynotes

TUESDAY | AUGUST 30



4:00 A New Era of Personalized Therapy: Using Tumor Neoantigens to Unlock the Immune System

Matthew J. Goldstein, M.D., Ph.D., Director, Translational Medicine, Neon Therapeutics, Inc.

Neon Therapeutics, Inc. launched in 2015 to focus on advancing neoantigen biology to improve cancer patient care. A neoantigen-based product engine will allow Neon to develop further treatment modalities including next-generation vaccines and T cell therapies targeting both personalized as well as shared neoantigens. The company's first trial will launch later this year investigating the combination of a personalized, vaccine with nivolumab in advanced Melanoma, NSCLC, and Bladder Cancer.



4:30 Emerging Innate Immune Targets for Enhancing Adaptive Anti-Tumor Responses

Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early Discovery, Merck Research Laboratories

Novel cancer immunotherapies targeting T cell checkpoint proteins have emerged as powerful tools to induce profound, durable regression and remission of many types of cancer. Despite these advances, multiple studies have demonstrated that not all patients respond to these therapies, and the ability to predict which patients may respond is limited. Harnessing the innate immune system to augment the adaptive anti-tumor response represents an attractive target for therapy, which has the potential to enhance both the percentage and rate of response to checkpoint blockade.



5:00 Reading Tea Leaves: The Dilemma of Prediction and Prognosis in Immunotherapy

Morganna Freeman, D.O., Associate Director, Melanoma & Cutaneous Oncology Program, The Angeles Clinic and Research Institute

With the rapid expansion of immunotherapeutics in oncology, scientifically significant advances have been made with both the depth and duration of antitumor responses. However, not all patients benefit, or quickly relapse, thus much scientific inquiry has been devoted to appropriate patient selection and how such obstacles might be overcome. While more is known about potential biomarkers, accurate prognostication persists as a knowledge gap, and efforts to bridge it will be discussed here.

Track Keynotes



Prasad S. Adusumilli, M.D., FACS, Deputy Chief of Translational & Clinical Research, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center



Roy D. Baynes, M.D., Ph.D., Senior Vice President and Head, Global Clinical Development, Merck Research Laboratories



Edward Cha, M.D., Ph.D., Associate Medical Director, Cancer Immunotherapy Franchise, Genentech



Robert Coffin, Ph.D., CEO, Replimmune



Jakob Dupont, M.D., Senior Vice President & CMO, OncoMed Pharmaceuticals



Kenneth Emancipator, M.D., Executive Medical Director, Companion Diagnostics, Merck & Co.



Ronald Herbst, Ph.D., Vice President, R&D; Head, Oncology Research, MedImmune



Robert Iannone, M.D., Senior Vice President & Head, Immuno-Oncology, Global Medicines Development, AstraZeneca



Ella Ioffe, Ph.D., Associate Director, Immune-Oncology, Regeneron Pharmaceuticals



David M. Kranz, Ph.D., Phillip A. Sharp Professor of Biochemistry, University of Illinois



Laszlo Radvanyi, Ph.D., Senior Vice President and Head, ImmunoOncology Translational Innovation Platform (TIP) EMD Serono



Zhen Su, M.D., MBA, Senior Vice President, Global Head of Medical Affairs Oncology, EMD Serono



James E. Wooldridge, M.D., CSO, Immuno-Oncology Clinical Development, Eli Lilly and Company

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
[Immuno-Oncology
Summit.com](http://Immuno-Oncology
Summit.com)



250 First Avenue
Needham, MA 02494
www.healthtech.com

Join the conversation!

in

You
Tube



#IOSUMMIT



Distinguished Faculty

Adam J. Adler

Ph.D., Professor,
Immunology, University
of Connecticut

Prasad S. Adusumilli

M.D., FACS, Deputy Chief of
Translational & Clinical, Re-
search, Thoracic Surgery,
Memorial Sloan-Kettering
Cancer Center

Omar Ali

Ph.D., Staff Scientist, Wyss
Institute for Biologically
Inspired Engineering,
Harvard University

Robert Anders

M.D., Ph.D., Associate
Professor, Pathology,
Johns Hopkins University

Philip M. Arlen

M.D., President & CEO,
Precision Biologics, Inc.

Roy D. Baynes

M.D., Ph.D., Senior Vice
President and Head, Global
Clinical Development, Merck
Research Laboratories

Stephen Beers

Ph.D., Associate Professor,
Cancer Immunology and
Immunotherapy, University
of Southampton

John Bell

Ph.D., Senior Scientist,
Centre for Innovative
Cancer Research, Ottawa
Hospital Research Institute,
Professor, Departments of
Medicine and Biochemistry,
Microbiology & Immunol-
ogy, University of Ottawa

Kevin Bonham

Ph.D., Curriculum Fellow,
Microbiology and Immu-
nology Department,
Harvard Medical School

Chris Boshoff

M.D., Ph.D., Vice President
and Head, Early, Develop-
ment, Translational and
Immuno-Oncology, Pfizer

Adrian Bot

M.D., Ph.D., Vice President,
Translational Sciences,
R&D, Kite Pharma Inc.

Caroline Breitbart

Ph.D., Vice President,
Translational Development,
Turnstone Biologics

Joshua Brody

M.D., Director, Lymphoma
Immunotherapy Program,
Icahn School of Medicine
at Mount Sinai

Tullia Bruno

Ph.D., Research Assistant
Professor, Immunology,
University of Pittsburgh

Manel Cascallo

Ph.D., Co-Founder,
President and CEO,
VCN Biosciences

Saso Cemerski

Ph.D., Associate
Principal Scientist, Merck
Research Laboratories

Edward Cha

M.D., Ph.D., Associate
Medical Director,
Cancer Immunotherapy
Franchise, Genentech

Brian Champion

Ph.D., Senior Vice
President, R&D, PsiOxus
Therapeutics Ltd

Zhao Chen

Ph.D., Investigator III,
Exploratory Immuno-On-
cology, Novartis Institutes
for BioMedical Research

Yeong "Christopher" Choi

Ph.D., Director, TCPF
and Assistant Professor
of Oncology, Center for
Immunotherapy, Roswell
Park Cancer Institute

Robert Coffin

Ph.D., CEO, Replimmune

Joe Conner

Ph.D., CSO, Virttu Biologics

Michael A. Curran

Ph.D., Assistant Professor,
Immunology; Scientific Di-
rector, ORBIT Platform MD
Anderson Cancer Center

Adil Daud

M.D., Professor, Hematol-
ogy/Oncology, University of
California, San Francisco;
Director, Melanoma Clinical
Research, UCSF Helen
Diller Family Comprehen-
sive Cancer Center

Anthony Davies

Ph.D., COO, 4D Molecular
Therapeutics

John Desjarlais

Ph.D., CSO, Xencor

Luis Alberto Diaz

M.D., Associate Professor,
Oncology, Johns Hopkins
Sidney Kimmel Comprehen-
sive Cancer Center

Gianpietro Dotti

M.D., Professor, Microbi-
ology and Immunology,
University of North Carolina

Jakob Dupont

M.D., Senior Vice
President & CMO, OncoMed
Pharmaceuticals

Kenneth Emancipator

M.D., Executive Medical
Director, Companion
Diagnostics, Merck & Co.

Boris Engels

Ph.D., Investigator,
Exploratory Immuno-On-
cology, Novartis Institutes
for Biomedical Research

Andrew M. Evens

D.O., Professor and Chief,
Hematology/Oncology,
Tufts University School
of Medicine; Director,
Tufts Cancer Center

Christopher R. Heery

M.D., Director, Clinical
Trials Group, Laboratory of
Tumor Immunology, Center
for Cancer Research

Christian S. Hinrichs

MD, Investigator,
Experimental Transplan-
tation and Immunology
Branch, Lasker Clinical
Research Scholar, NIH

Mark J. Federspiel

Ph.D., Professor and Direc-
tor, Viral Vector Production
Laboratory, Mayo Clinic

Continued on next page...

Cover

Conference-at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit Opportunities

Training Seminar

Agenda

Hotel & Travel Information

Registration Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

Continued from previous page...

Patrick Forde

M.D., Assistant Professor, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Morganna Freeman

D.O., Associate Director, Melanoma & Cutaneous Oncology Program, The Angeles Clinic and Research Institute

Bruce Freemark

Ph.D., Research Director, Preclinical Oncology, Peregrine Pharmaceuticals

Jennifer Gansert

Ph.D., Executive Director, Global Development Lead, Amgen, Inc.

Sanja Gauthier

M.D., Senior Medical Director, Medical Safety Evaluation, Pharmacovigilance and Patient Safety, AbbVie

Tariq Ghayur

Ph.D., Distinguished Research Fellow, AbbVie Bioresearch Center

Oliver Ghoibrial

Ph.D., Principal Scientist, Translational Informatics, Sanofi

Geoffrey T. Gibney

M.D., Medical Oncologist, Georgetown-Lombardi Comprehensive Cancer Center

Sacha Gnjatich

Ph.D., Associate Professor, Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai

Matthew J. Goldstein

M.D., Ph.D., Director, Translational Medicine, Neon Therapeutics, Inc.

Jeffrey Hanke

Ph.D., CSO, Tesaro

Ronald Herbst

Ph.D., Vice President, R&D; Head, Oncology Research, MedImmune

Alex Yee-Chen Huang

M.D., Ph.D., Associate Professor, Pediatrics, Pathology & Biomedical Engineering, Case Western Reserve University School of Medicine

Robert Iannone

M.D., Senior Vice President & Head, Immuno-Oncology, Global Medicines Development, AstraZeneca

Ella Ioffe

Ph.D., Associate Director, Immune-Oncology, Regeneron Pharmaceuticals

Pushpa Jayaraman

Ph.D., Investigator II, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

Suchita Jhunjhunwala

Ph.D., Scientist, Bioinformatics, Genentech

Frank R. Jones

Ph.D., Chairman & CEO, Etubics Corporation

Jennifer C. Jones

M.D., Ph.D., Assistant Clinical Investigator, Molecular Immunogenetics & Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health

Karin Jooss

Ph.D., CSO, Gritstone Oncology

Pawel Kalinski

M.D., Ph.D., Professor, Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute

Cris Kamperschroer

Ph.D., Associate Research Fellow, Drug Safety R&D, Pfizer

Vassiliki Karantzis

M.D., Ph.D., Director, Clinical Research Oncology, Merck Research Laboratories

Noriyuki Kasahara

M.D., Ph.D., Professor, Departments of Cell Biology and Pathology, Co-Leader, Viral Oncology Program, University of Miami

David Kaufman

Ph.D., Executive Director, Clinical Oncology, Merck Research Laboratories

Howard L. Kaufman

M.D., FACS, Associate Director, Clinical Sciences, Rutgers Cancer Institute of New Jersey; Professor and Chief, Division of Surgical Oncology, Rutgers Robert Wood Johnson Medical School

Llew Keltner

M.D., Ph.D., CEO, EPISTAT

Arthur M. Krieg

M.D. CEO, Checkmate Pharmaceuticals

David Kim

M.D., CEO & Co-Founder, 4D Molecular Therapeutics; Adjunct Professor, Bioengineering, University of California, Berkeley

Keith L. Knutson

Ph.D., Professor, Immunology, Mayo Clinic

David M. Kranz

Ph.D., Phillip A. Sharp Professor of Biochemistry, University of Illinois

Arthur M. Krieg

M.D. CEO, Checkmate Pharmaceuticals

Kyle Landgraf

Ph.D., Senior Scientist, Discovery Research, AvidBiotics

Jane Lebkowski

Ph.D., President & CSO, Research and Development, Asterias Biotherapeutics

Michael Lim

M.D., Associate Professor, Neurosurgery, Oncology and Radiation Oncology, Johns Hopkins University School of Medicine

Douglas Linn

Ph.D., Senior Scientist, In Vivo Pharmacology, Merck

Konstantin M. Linnik

Ph.D., Partner, Intellectual Property, Nutter, McClennen & Fish, LLP

Jason J. Luke

M.D., FACP, Assistant Professor, Medicine, Melanoma and Developmental Therapeutics Clinics, University of Chicago Medical Center

Ravi Madan

M.D., Clinical Director, Genitourinary Malignancies, Branch, National Cancer Institute, National Institutes of Health

Jennifer Mataraza

Ph.D., Senior Investigator, Immune Oncology, Novartis Institutes for BioMedical Research

Patricia McCoon

Ph.D., Principal Scientist, Oncology IMED Translational Science, AstraZeneca Pharmaceuticals

Miriam Merad

M.D., Ph.D., Chair, Cancer Immunology, Oncological Sciences, Tisch Cancer Institute, Mount Sinai Hospital

Todd Metzger

Ph.D., Senior Scientist, Cancer Immunology, Pfizer

Janter Meulen

M.D., Dr.habil., DTM&H, CSO, Immune Design

Richard A. Morgan

Vice President, Immuno-therapy, bluebird bio

Spyro Mousses

Ph.D., President, Systems Imagination Inc.

Matthew Mulvey

Ph.D., CEO, BeneVir

Kuldeep Neote

Ph.D., Senior Director, New Ventures, J&J Innovation Center Boston

Cokey Nguyen

Ph.D., Vice President, R&D, Enumeral

Fares Nigim

M.D., Massachusetts General Hospital

Patrick Alexander Ott

M.D., Ph.D., Assistant Professor, Medicine, Dana-Farber Cancer Institute

Michael J. Overman

M.D., Associate Professor, Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center

Joseph Pearlberg

M.D., Ph.D., Senior Medical Director, Infinity Pharmaceuticals

Rodney Prell

Ph.D., DABT, Principal Scientist/Toxicologist, Safety Assessment, Genentech

Maire Quigley

Ph.D., Research Investigator, Cell Process Development, Cell & Gene Therapies, Novartis

Laszlo Radvanyi

Ph.D., Senior Vice President; Head of Immuno-Oncology Translational Innovation Platform (TIP), EMD Serono

Sheila Ranganath

Ph.D., Associate Director, R&D, Enumeral Biomedical Corporation

Paul Rennett

Ph.D., President & CSO, Aleta Biotherapeutics Inc.

Aaron Ring

M.D., Ph.D., Assistant Professor, Immunobiology, Yale University School of Medicine

Scott Rodig

M.D., Ph.D., Associate Professor, Pathology, Harvard Medical School; Associate Pathologist, Pathology, Brigham & Women's Hospital

Arjan Roosen

Vice President, GMP Solutions & Manufacturing, Collectis

Michael Rosenzweig

Ph.D., Executive Director, Biology-Discovery, IMR Early, Discovery, Merck Research Laboratories

Stephen J. Russell

M.D., Ph.D., Professor, Mayo Clinic

Catherine Sabatos-Peyton

Ph.D., Senior Investigator, Novartis Institutes for BioMedical Research

Christian Schmees

Ph.D., Head of Tumor Biology, Molecular Biology Department, NMI Natural and Medical Sciences Institute at the University of Tübingen

Taylor Schreiber

M.D., Ph.D., CSO, Heat Biologics, Inc.

Armon Sharei

Ph.D., CEO, SQZ Biotechnologies

Michail Sitkovsky

Ph.D., Professor, Eleanor W. Black Chair, and Director, New England Inflammation and Tissue Protection Institute, Northeastern University

Craig L. Slingluff Jr.

M.D., Joseph Helms Farrow Professor of Surgery; Vice-Chair for Research; Director, Human Immune Therapy Center, University of Virginia School of Medicine

Susan R. Slovin

M.D., Ph.D., Medical Oncologist, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center

Elena Spanjaard

Ph.D., Director, Worldwide Research & Development, Regulatory Affairs, Pfizer

David M. Spencer

Ph.D., CSO, Bellicum Pharmaceuticals

Pramod K. Srivastava

Ph.D., M.D., Professor, Immunology and Medicine, Director, Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine

Zhen Su

M.D., MBA, Senior Vice President, Global Head of Medical Affairs Oncology, EMD Serono

Brad Thompson

Ph.D., CEO, Oncolytics Biotech

Stephen Thorne

Ph.D., Professor and Scientific Advisor, Inventor, Western Oncolytics

Wolfgang Uckert

Associate Professor, Department of Cell Biology and Gene Therapy, Humboldt University Berlin

Marit van Buuren

Ph.D., Scientist, Immunology, Neon Therapeutics

Andrea van Elsas

Ph.D., CSO, Aduro Biotech Europe, The Netherlands

Janaki Veeraraghavan

Ph.D., Biologist, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, FDA

Luis M. Vence

Ph.D., Scientific Manager, Immunology, MD Anderson Cancer Center

Alena Gros Vidal

Ph.D., Research Fellow, Surgery Branch, National Cancer Institute

Antti Vuolanto

Ph.D., Executive Vice President, Targovax

Jeffrey Wallin

Ph.D., Group Leader, Early Stage Oncology Biomarker Development, Genentech

Steffen Walter

Ph.D., CSO, Immatics Biotechnologies GmbH

Chan Whiting

Ph.D., Director, Immune Monitoring/Biomarker Development, Aduro Biotech

Jon Wigginton

M.D., CMO & Senior Vice President, Clinical Development, MacroGenics

Andy Williams

Ph.D., Companion Diagnostics Group Leader, Cancer Immune Therapies, Genentech

Daniel Williams

Head, UK Research Operations, Adaptimmune

K. Dane Wittrup

Ph.D., Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology

James E. Wooldridge

Ph.D., CSO, Immuno-Oncology Clinical Development, Eli Lilly and Company

John Wrangle

M.D., Assistant Professor, Medicine, Hematology/Oncology, Medical University of South Carolina

Jianda Yuan

M.D., Ph.D., Director, Translational Immuno-Oncology Research, Merck Research Labs

Jonathan Zalevsky

Ph.D., Vice President, Biology & Preclinical Development, Nektar Therapeutics

Xingxing Zang

Ph.D., Associate Professor, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immunology-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com



Short Courses

Tuesday & Thursday Dinner Short Courses

TUESDAY, AUGUST 30

6:30-9:00 pm SC1: Targeting the Cancer Mutanome

Laszlo Radvanyi, Ph.D., Senior Vice President; Head of Immuno-Oncology Translational Innovation Platform (TIP), EMD Serono

Luis M. Vence, Ph.D., Scientific Manager, Immunology, MD Anderson Cancer Center

Alena Gros Vidal, Ph.D., Research Fellow, Surgery Branch, National Cancer Institute

Suchit Jhunjhunwala, Ph.D., Scientist, Bioinformatics, Genentech

Emerging sequencing and bioinformatics technologies are now giving researchers new perspectives on the mutations in patient specific antigens, now collectively known as the cancer mutanome. Our dinner short course offers academic and industry perspectives on the analytical and computational methods used to identify neo-epitopes within a mutanome that are candidates for therapeutic intervention – and the potential applications of this knowledge in patient diagnostics and immunotherapy. An open discussion format will allow those working in this space to share insights and experiences on how to advance this new field into clinical practice.

6:30-9:00 pm SC2: Bispecific Antibody Development for Immunotherapy

Sanja Gauthier, M.D., Senior Medical Director, Medical Safety Evaluation, Pharmacovigilance and Patient Safety, AbbVie

Cris Kamperschroer, Ph.D., Associate Research Fellow, Drug Safety R&D, Pfizer

Bispecific molecules designed to recruit T cells and induce them to kill tumor cells are showing promise as cancer immunotherapies. There are challenges to developing these molecules, including safety concerns related to the intended pharmacology of T cell activation. This presentation will cover the nonclinical development of a specific T cell targeting bispecific molecule, its key safety concerns, and approaches to mitigate the concerns.

This short course will address:

- Nonclinical development of a T cell targeting bispecific molecule
- Benefit/risk of bifunctional antibodies in oncology clinical development

THURSDAY, SEPTEMBER 1

6:00-9:00 pm SC3: ThinkTank: PD-L1 Assays for Biomarkers and Companion Diagnostics

Moderator: Kenneth Emancipator, M.D., Executive Medical Director, Companion Diagnostics, Merck & Co.

Panelists: Robert Anders, M.D., Ph.D., Associate Professor, Pathology, Johns Hopkins University

Adil Daud, M.D., Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Andy Williams, Ph.D., Companion Diagnostics Group Leader, Cancer Immune Therapies, Genentech

Jianda Yuan, M.D., Ph.D., Director, Translational Immuno-Oncology Research, Merck Research Labs

The facilitated discussion with expert panelists and audience participation will address the key issues in development of PD-L1 assays for biomarkers and companion diagnostics in cancer immunotherapy. Coverage will include development and standardization of PD-L1 assays, validation of PD-L1 as a predictive biomarker and utility in clinical trials, development of PD-L1 as a companion diagnostic, and regulatory considerations in using companion diagnostics to guide cancer immunotherapy.

6:00-9:00 pm SC4: Adoptive Therapy With CAR T Cells

Instructor to be Announced

Adoptive cell therapy (ACT) is causing a great deal of excitement in the clinical research community due to its ability to utilize a patient's own immune cells to effectively recognize and attack cancer cells. One well-studied modality of ACT employs genetically modified chimeric antigen receptor expressing T cells (CAR T) to target surface proteins

MEDIA PARTNERS



overexpressed on cancer cells. This strategy is unique from other forms of ACT, as target recognition is not MHC restricted. CAR T cells have demonstrated significant clinical potency in the treatment of certain leukemias, and trials targeting solid tumor indications are now commencing.

This short course will address:

- History of CAR T development
- Strategies for effective gene delivery
- Cell production platforms and processes
- Initial clinical successes treating acute lymphoblastic leukemia
- Associated toxicities and clinical management
- Challenges associated with targeting solid tumor antigens
- The dilemma posed by the solid tumor microenvironment
- Novel CAR T designs and technologies

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immunology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

Sponsorship, Exhibit, & Lead Generation Opportunities

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space, branding and networking with specific prospects. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company's needs and budget. Signing on early will allow you to maximize exposure to qualified decision-makers.

Podium Presentations

Available Within the Main Agenda!

Showcase your solutions to a guaranteed, targeted audience through a 15- or 30-minute presentation during a specific conference program, breakfast, lunch, or separate from the main agenda within a pre-conference

workshop. Package includes exhibit space, on-site branding, and access to cooperative marketing efforts by CHI. For the luncheon option, lunches are delivered to attendees who are already seated in the main session room. Presentations will sell out quickly, so sign on early to secure your talk!

One-on-One Meetings

Select your top prospects from the pre-conference registration list. CHI will reach out to your prospects and arrange the meeting for you. A minimum number of meetings will be guaranteed, depending on your marketing objectives and needs. A very limited number of these packages will be sold.

Exhibit

Save \$300 Sign up by May 20, 2016

Exhibitors will enjoy facilitated networking opportunities with qualified

delegates. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

Additional branding and promotional opportunities are available, including:

- Mobile App
- Hotel Room Keys
- Footprint Trails
- Conference Tote Bags
- Literature Distribution (Tote Bag Insert or Chair Drop)
- Badge Lanyards
- Program Guide Advertisement

Looking for additional ways to drive leads to your sales team?

CHI's Lead Generation Programs will help you obtain more targeted, quality leads throughout the year. We will mine our database of 800,000+ life science professionals to your specific needs. We guar-

antee a minimum of 100 leads per program! Opportunities include:

- Whitepapers
- Web Symposia
- Custom Market Research Surveys
- Podcasts

For sponsorship & exhibit information, please contact:


Companies A-K:

Ilana Quigley
Sr Business
Development Manager
781-972-5457
iquigley@healthtech.com

Companies L-Z:


Joseph Vacca, M.Sc.
Associate Director,
Business Development
781-972-5431
jvacca@healthtech.com

Demographics for CHI Immuno-Oncology Conferences




COMPANY TITLE

Commercial (Biotech + Pharma)	68%
Academic	17%
Healthcare	8%
Financial	3%
Government	2%
Services/Societies	1%
Other (CRO + Press)	1%



GEOGRAPHIC LOCATION

USA	70%
US Breakdown	
East Coast	60%
West Coast	30%
Midwest	10%
Europe	18%
Asia	7%
Rest of World	5%



DELEGATE TITLE

Scientist/Technologist	38%
Executive + Director	36%
Professor	11%
Manager	7%
Sales & Marketing	4%
Other	4%

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com



Immunology for Drug Discovery Scientists

TRAINING SEMINAR: IMMUNOLOGY FOR DRUG DISCOVERY SCIENTISTS

Instructor: Kevin Bonham, Ph.D., Lecturer, Microbiology and Immunobiology, Harvard Medical School

In order to detect the presence of potential pathogens, the immune system must interact with every body system and circulate through every tissue. The weight of the microbial threat has led to the evolution of a unique biological skill set that make the immune system incredibly powerful, but also incredibly dangerous. These unique skills and systemic reach mean that the immune system touches almost every human disease, either causally or as an avenue for therapy. In this course, we will explore therapeutic approaches that harness our knowledge of the immune system to treat human disease. From vaccines to cancer (not to mention cancer vaccines!) and diabetes to IBD, we will explore how the immune system can be shaped, engineered, and harnessed by exploring specific examples of current and future therapeutics, and the immunology behind them.

TOPICS INCLUDE:

Introduction to the Unique Biology of the Immune System Pathogen Detection and Inflammation (Innate Immunity)

- Cell-intrinsic detection and response
- Local detection, paracrine signaling
- Systemic responses

Cellular Immunity, Cytotoxicity

- NK-cells
- CD8+ T-cells
- Macrophages
- CD4+ T-cells

Antibodies

- B-cell biology
- Diversity of antibody function
- Complement fixation

Immune System Interactions (The Big Picture)

- Lymphocyte development
- Antigen presentation (B-cell/T-cell, APC/T-cell, DC/B-cell)
- CD4+ T-cell redux

Engineering Immunity – Monoclonal Antibody Therapies

MAB #1 - TGN1412

- Anti-CD28 monoclonal therapy - intended to activate Treg cells
- Actually activated all T-cells, caused cytokine storm in healthy volunteers, severe, permanent damage

MAB #2 - Natalizumab

- Anti $\alpha 4$ integrin - blocks T-cells from entering brain, highly effective treatment for MS
- Great example of rationally-designed therapy, minimal side effects
- Fewer side-effects than most anti-inflammatory drugs, increased risk for PML

Receptor/Fc Hybrids - CD4-Fc anti-HIV

MAB Summary

- Good for inhibiting things, sometimes can activate
- Target must be cell-extrinsic

Engineering Immunity #2 - CAR-T Cells

The Trouble with Neoantigens

How Many Treatments Does it Take to Cure Melanoma?

Molding Immunity - Vaccines

- History of vaccine approaches - mostly antibodies
- Vaccine approaches - better adjuvants/better antigens
- Vaccine approaches - prime and pull
- Vaccine approaches - skip the vaccine (gene therapy)

Harnessing Immunity - Anti-Cancer Approaches

Checkpoint Blockade Therapies

- History
- Targets

Cancer Vaccines

Limitations (Neoantigens, Autoimmunity)

Each CHI Training Seminar offers 1.5 days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.

Each person registered specifically for the training seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the seminar, but after these have been distributed no additional books will be available.

Though CHI encourages track hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because Seminars are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and not engage in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.



Dr. Kevin Bonham is a Curriculum Fellow for the Microbiology and Immunobiology Department at Harvard Medical School, and the principal instructor for the Masters of Medical Sciences program in Immunology. He received his Ph.D. from Harvard in the lab of Jonathan Kagan, where he studied the cell biology and biochemistry of Toll-like Receptor signaling and innate immune pattern recognition.

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

MON-TUE | AUGUST 29-30



Immunomodulatory Therapeutic Antibodies for Cancer

Exploring the Evolution of Novel Immunotherapies Based on Checkpoint Inhibitors, Costimulatory Agonists and Emerging Targets

Recommended Dinner Short Course*

Targeting the Cancer Mutanome

*Separate registration required, please see [Short Courses](#) for details

MONDAY, AUGUST 29

7:30 am Registration & Morning Coffee

8:25 Chairperson's Opening Remarks

Tariq Ghayur, Ph.D., Distinguished Research Fellow, AbbVie Bioresearch Center

8:30 OPENING KEYNOTE PRESENTATION: IMMUNOTHERAPY FOR CANCER: THE PROMISE AND CHALLENGES AHEAD

Ronald Herbst, Ph.D., Vice President, R&D; Head, Oncology Research, MedImmune
Immune-evasion is a hallmark of cancer and enhancement of the anti-cancer immune response by targeting checkpoint pathways, such as CTLA-4 and PD-1/PD-L1, is showing significant promise. However, a subset of patients fails to benefit from immune therapy. Going forward it will be key to better understand the immunologic diversity within and across indications, and to identify markers of response (or no response) to therapy to further increase the benefit to patients.

UNDERSTANDING THE MECHANISMS OF ACTION FOR IMMUNOMODULATORY ANTIBODIES

9:00 Lessons Learned from Studies of Checkpoint Blockade Toxicity

Geoffrey T. Gibney, M.D., Medical Oncologist, Georgetown-Lombardi Comprehensive Cancer Center
Recent developments in targeted immune checkpoint blockade have revolutionized treatment approaches in patients with advanced malignancies. While durable responses are seen, checkpoint therapies are associated with a range of immune-related toxicities that can complicate patient care. Combination strategies so far have led to even higher

rates of immune events. Most severe toxicities are manageable with corticosteroids and other immunomodulatory agents. The current data on checkpoint blockade toxicities will be reviewed.

9:30 Coffee Break

10:00 Anti-Hypoxia-A2-Adenosinergic Co-Adjuvants to Enable the Full Anti-Tumor Capacities of T- and Natural Killer Cells During Immunotherapies of Cancer

Stephen Hatfield, Ph.D., Research Scientist, New England Inflammation and Tissue Protection Institute, Northeastern University
The presentation introduces the adenosine-generating CD73 ecto-enzyme as a potential drug target and biomarker of the most resistant human tumors. In addition, oxygenation agents join antagonists of A2A Adenosine Receptors as novel checkpoint inhibitors that reprogram the TME away from immunosuppression and have promise if used in combination with existing cancer immunotherapies.

10:30 The Role of Immune Biomarkers in Offering a Standardized Way of Evaluating the *in vivo* Behavior of Cancer Immunotherapies

Susan R. Slovin, M.D., Ph.D., Medical Oncologist, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center
Major initiatives are ongoing to establish and validate in clinical trials a platform of biomarkers that can be used to assess biologic changes and treatment responses in solid tumors treated with novel immune drugs. The identification and relevance of biomarkers in trials with immunologic agents can vary with the drug used. How to incorporate the metrics of biomarkers into immunotherapy trials and their validation is a major focus of trial design.

11:00 Anti-PD-1 Immunomodulatory Antibodies with Unique Mechanisms of Action

Sheila Ranganath, Ph.D., Associate Director, R&D, Enumeral Biomedical Corporation
Using Enumeral's proprietary single cell immune-profiling technology, we discovered a distinct anti-PD-1 antibody with a potentially differentiated mechanism of action. This antibody, 244C8, does not compete with currently marketed anti-PD-1 antibodies for PD-1 binding. Further, 244C8 elicits

greater T cell activation in ex vivo human cell-based assays than currently marketed anti-PD-1 antibodies. 244C8 has been humanized for preclinical testing in preparation for Phase I clinical studies.

11:30 Tumor-Localized Costimulatory T Cell Engagement with Bispecific CD137-Agonists

Louis Matis, M.D., Senior Vice President, Chief Development Officer, Pieris Pharmaceuticals, Inc.

We describe the generation and characterization of the CD137/HER2 and CD137/GPC-3 bispecifics designed to promote CD137 clustering in the tumor microenvironment by bridging CD137- positive T cells with target positive tumor cells, thereby providing a potent costimulatory signal to tumor antigen-specific T cells.

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Session Break

EMERGING TARGETS AND STRATEGIES FOR CANCER IMMUNOTHERAPY

1:25 Chairperson's Remarks

Adam J. Adler, Ph.D., Professor, Immunology, University of Connecticut

1:30 Bi- and Multi-Specific Biologics for Cancer Immunotherapy: Selecting Target Combinations and Designing Biologics to Modulate Anti-Tumor T Cell Functions

Tariq Ghayur, Ph.D., Distinguished Research Fellow, AbbVie Bioresearch Center

The presentation will discuss how high throughput functional bioassays have been used to select combinations of mAbs to either the same target (different epitopes) or different targets for generating dual-specific DVD-Ig molecules with additive and/or synergistic activity. The talk will also describe the application of new multi-specific formats in understanding the biology of T cell activation by co-ligating CD3 and co-receptors and to design molecules to address specific unmet needs.

Sponsored by:



Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

2:00 T Cell Activation and Pre-Clinical Anti-Tumor Efficacy of Anti-Lag3 Mabs Is Independent of their Lag-3-Mhc Class II Blocking Capacity

Saso Cemerski, Ph.D., Associate Principal Scientist, Merck Research Laboratories

LAG-3 is a MHC-II-interacting receptor that hampers T cell activation. We assessed the relationship between anti-LAG-3 antibody-induced efficacy and the ability to block LAG-3-MHCII interactions. We compared the bioactivity of two distinct anti-mLAG-3 antibodies that differ in their ability to block LAG-3-MHCII interactions. We demonstrated that anti-LAG-3 antibody efficacy is not associated with their ability to disrupt LAG-3-MHCII interaction, suggesting they could enhance both CD4+ and CD8+ T cell function.

2:30 Pathways and Mechanisms Engaged by OX40 Plus 4-1BB Dual Costimulation Immunotherapy

Adam J. Adler, Ph.D., Professor, Immunology, University of Connecticut

Dual costimulation with CD134 plus CD137 agonists elicits powerful therapeutic tumor immunity by priming robust CD8+ CTL, and CD4 T cells that are cytotoxic and provide both antigen-linked and non-linked help. Further, dual costimulated T cells can be triggered to elaborate effector functions not only by antigen, but also TCR-independently through cytokine combinations such as IL-12 or IL-2 plus either of the IL-1 family members IL-33 or IL-36.

3:00 Refreshment Break

3:30 High Dimensional Cell Analysis of Early Lung Tumor Immune Contexture

Miriam Merad, M.D., Ph.D., Chair, Cancer Immunology, Oncological Sciences, Tisch Cancer Institute, Mount Sinai Hospital

Despite unprecedented clinical response of advanced NSCLC to checkpoint blockade, a comprehensive understanding of the immune microenvironment of early stage NSCLC has not been done. Here we will present high dimensional single-cell analysis of immune changes that occurs in the vicinity of early lung NSCLC. Our results provide a rationale for testing whether modulation of the lung tumor immune microenvironment can promote anti-tumor immunity, prevent tumor relapse and transform the outcome of patients with early lung cancer.

4:00 Inducing Neo-Antigen Specific T Cells from the Naïve Repertoire

Marit van Buuren, Ph. D., Scientist, Immunology, Neon Therapeutics

The recognition of neo-antigens on human cancer has strongly been connected to the clinical success of immune therapies. Neon Therapeutics Inc. aims

to generate neo-antigen specific vaccines and T cell therapies that are tailored for each individual patient. Here we will present the platform that Neon has developed to generate a neo-antigen specific T cell product for the use of adoptive cell transfer.

4:30 Targeting TIM-3 and LAG-3

Jeffrey Hanke, Ph.D., CSO, Tesaro

Strategies to activate exhausted tumor-specific T cells, including the use of monoclonal antibodies (mAb) that block the negative costimulatory receptors CTLA-4 and PD-1/PDL1, are proving effective in a number of cancer types. However, only a subset of patients respond to these therapies, and resistance is increasingly observed. The role of TIM3 and LAG3 will be discussed.

5:00 End of Day

TUESDAY, AUGUST 30

8:00 am Morning Coffee

PROTEIN ENGINEERING FOR CANCER IMMUNOTHERAPIES

8:25 Chairperson's Opening Remarks

John Desjarlais, Ph.D., CSO, Xencor

8:30 The Role of Antibody Isotype and Fc Receptor Interactions in Engineering Cancer Immunotherapies

Stephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton

Exciting clinical results with checkpoint-blocking mAb have revived the belief that the immune system holds the key to controlling cancer. Here we show that immunostimulatory mAb can employ multiple mechanisms in tumors, and that the mechanism used depends on mAb isotype and FcγR availability. These data have broad implications for selecting tumor immune targets and engineering immunomodulatory mAb; illustrating the necessity to determine all potential mechanisms of action to maximize activity and potential clinical utility.

9:00 Immune Checkpoint Inhibition by High-Affinity Receptor Decoys: Good Things Come in Small Packages

Aaron Ring, M.D., Ph.D., Assistant Professor, Immunobiology, Yale University School of Medicine

Immune checkpoints have largely been therapeutically targeted using monoclonal antibodies. However, non-antibody biologics may offer potential advantages in the context of tumor immunotherapy. This talk will highlight two engineered ultra high-affinity decoys of PD-1 and SIRPα—checkpoints of the adaptive and innate immune systems, respectively.

These agents illustrate the potential for small protein therapeutics as immunotherapeutics, components of cell-based therapies, and diagnostic agents of immune function and tumor immunogenicity.

9:30 Targeting Fc Effector Functions to Tumor-Expressed Integrins for Synergistic Innate and Adaptive Immunotherapy

K. Dane Wittrup, Ph.D., Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology

Anti-tumor antibodies combined with extended-PK IL-2 leads to significant immunotherapeutic responses in large established syngeneic tumors in mice. In order to extend this approach to tumor types for which specific antibodies are not available, we have constructed an Fc fusion to a small knottin protein with broad binding specificity to RGD-binding integrins. This pseudo-mAb exhibits strong efficacy in preclinical models and generates a T-cell dependent protective adaptive immune response.

10:00 Sponsored Presentations (Opportunities Available)

10:30 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

11:15 Tumor-Specific Antibodies Engineered to Bind NKG2D Activate both NK and T-Cells

Kyle Landgraf, Ph.D., Senior Scientist, Discovery Research, AvidBiotics

NK and T-cells utilize the NKG2D receptor to destroy cancer cells expressing stress ligands. However, tumors deploy strategies to evade this surveillance pathway. Using structure-guided phage display, NKG2D stress ligands have been engineered as effector domains to convert tumor-specific antibodies into dual NK/T-cell activators through NKG2D engagement. These antibodies can stimulate IFNγ production and degranulation of NK and T-cells, providing rationale for their use in combination with checkpoint therapies.

11:45 Bispecific Antibodies for T Cell Recruitment and Dual Checkpoint Blockade

John Desjarlais, Ph.D., CSO, Xencor

We have optimized a plug-and-play, Fc-containing bispecific antibody platform with high stability, efficient production, and antibody-like pharmacokinetics. This optimized bispecific format resembles a standard monoclonal antibody, with one of the Fab arms replaced by a stability-optimized single-chain Fv (scFv) (scFv-Fab-Fc). We will present application of the platform to generate a broad pipeline of CD3 bispecifics for T cell redirection and dual checkpoint blockade bispecifics for T cell activation.

12:15 pm Close of Immunomodulatory Therapeutic Antibodies for Cancer

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

MON-TUE | AUGUST 29-30



Oncolytic Virus Immunotherapy

Unlocking Oncolytic Virotherapies: From Science to Commercialization

Recommended Dinner Short Course*

Targeting the Cancer Mutanome

*Separate registration required, please
see [Short Courses](#) for details

MONDAY, AUGUST 29

7:30 am Registration & Morning Coffee

REALIZING THE POTENTIAL OF ONCOLYTIC VIRUS IMMUNOTHERAPY

8:25 Chairperson's Opening Remarks

*Brian Champion, Ph.D., Senior Vice President,
R&D, PsiOxus Therapeutics Ltd*

8:30 T-Vec: From Market Approval to Future Plans

*Jennifer Gansert, Ph.D., Executive Director,
Global Development Lead, Amgen, Inc.*

9:00 Oncolytic Virotherapies as a Single Shot Cure?

Stephen J. Russell, M.D., Ph.D., Professor, Mayo Clinic
Oncolytic virotherapy is increasingly used as a cancer immunotherapy. However, certain oncolytic viruses can also mediate wholesale tumor destruction independently of an antitumor immune response. This is the oncolytic paradigm, where a cytolytic virus with preferential tumor tropism spreads extensively at sites of tumor growth and directly kills the majority of the tumor cells in the body leaving only a few uninfected tumor cells to be controlled by the concomitant antitumor immune response.

9:30 Coffee Break

UNDERSTANDING MECHANISMS OF ACTION

9:55 Chairperson's Remarks

*Fares Nigim, M.D., Massachusetts General
Hospital and Harvard Medical School*

10:00 Designing Clinical Trials to Elucidate Oncolytic Virus Mechanisms-of-Action

*Caroline Breitbart, Ph.D., Vice President,
Translational Development, Turnstone Biologics*

Oncolytic viruses have been shown to target tumors by multiple complementary mechanisms-of-action, including direct oncolysis, tumor vascular targeting and induction of anti-tumor immunity. Phase I/II clinical trials can be designed to validate these mechanisms. Development experience of an oncolytic vaccinia virus and a novel rhabdovirus oncolytic vaccine will be summarized.

10:30 Seprehvir, an Icp34.5 Deleted OHSV with Both Direct and Covert Modes of Action

Joe Conner, Ph.D., CSO, Virttu Biologics

Seprehvir, an oncolytic HSV, is a complex biologic with multi-mechanistic modes of action. Lytic cytotoxicity, induction of Th1 cytokines/chemokine responses, recruitment of innate and adaptive immune cells and changes in the tumor microenvironment can enhance therapeutic efficacy in combination with other anti-cancer agents. How these modes of action intersect with PD-1 checkpoint inhibitors, CAR T cells and small molecule targeted therapies will be discussed.

11:00 The Mechanism of Action of Oncos-102, Oncolytic Adenovirus-Based Immune Activator

*Antti Vuolanto, Ph.D., Executive
Vice President, Targovax*

ONCOS-102 is an engineered human serotype 5 adenovirus expressing GMCSF. A total of 12 cancer patients were treated with repeated intratumoral injections of ONCOS-102 in a Phase I study. Eleven out of twelve patients showed a post-treatment increase in tumor-infiltrating immune cells including CD8+ T cells and two patients showed systemic induction of tumor specific CD8+ T cells.

11:30 Sponsored Presentations (Opportunities Available)

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Session Break

BIOMARKERS AND IMPROVING VIRUS ACTIVITY

1:25 Chairperson's Remarks

*David Kirn, M.D., CEO & Co-Founder, 4D
Molecular Therapeutics & Adjunct Professor
of Bioengineering, UC Berkeley*

1:30 New Biomarkers that Predict Response to Oncolytic Virus Immunotherapy

*Howard L. Kaufman, M.D., FACS, Associate
Director, Clinical Sciences, Rutgers Cancer
Institute of New Jersey; Professor and
Chief, Division of Surgical Oncology, Rutgers
Robert Wood Johnson Medical School*

T-VEC is the first oncolytic virus approved for the treatment of melanoma, and will soon enter clinical trials for treatment of other cancers. Further studies using T-VEC in combination with T cell checkpoint inhibitors are underway and showing promising early results. The identification of predictive biomarkers of response would be helpful for improving patient selection and optimizing therapeutic outcomes. We have recently focused on HSV-1 entry receptors and oncogenic signaling pathways within cancer cells as potential biomarkers of T-VEC response.

2:00 Therapeutic Viral Vector Evolution: A Robust Platform for the Discovery of Optimized Vectors

*David Kirn, M.D., CEO & Co-Founder, 4D
Molecular Therapeutics; Adjunct Professor,
Bioengineering, University of California, Berkeley*
Therapeutic virus vectors hold great promise for cancer gene and immunotherapy. However, novel vectors with improved efficacy are needed. Therapeutic Vector Evolution is a discovery platform from which optimized and proprietary viral vectors can be identified with beneficial characteristics of interest.

2:30 Enhancing Oncolytic Virus Activity by Engineering of Artificial MicroRNAs

*John Bell, Ph.D., Senior Scientist, Centre for Innovative
Cancer Research, Ottawa Hospital Research Institute,
Professor, Departments of Medicine and Biochemistry,
Microbiology & Immunology, University of Ottawa*
We have devised a novel strategy to enhance the ability of oncolytic viruses to infect malignant cells

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

by expressing artificial microRNAs (amiRNAs) from the oncolytic virus genome. We have screened a variety of amiRNAs and identified a number that enhance virus replication within tumour but not normal cells. The characterization of these miRNAs and their targets will be discussed.

3:00 Refreshment Break

3:30 KEYNOTE PRESENTATION: ONCOLYTIC IMMUNOTHERAPY IN THE ERA OF CHECKPOINT BLOCKADE

Robert Coffin, Ph.D., CEO, Replimmune

Oncolytic immunotherapy treats cancer by virus-mediated tumor cell lysis and generation of a patient specific cancer vaccine, including to neo-antigens, *in situ* directly in the patient. Both are likely important for the clinical efficacy seen with single agent use, and also for the clinical synergy observed with immune checkpoint blockade. Background and data supporting single agent and combination use will be discussed, and future directions described.

4:00 Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics

*Brian Champion, Ph.D., Senior Vice President,
R&D, PsiOxus Therapeutics Ltd.*

We have developed a systemically deliverable, oncolytic adenoviral platform for directing efficient and selective local production of a combination of bio-therapeutic agents selectively within the tumor. This has the potential for enhanced efficacy while reducing side effects by limiting systemic exposure. Up to three separate biomolecules can be encoded in the same virus without affecting oncolytic properties of the virus.

4:30 Immuno-Oncolytic Virus- es as Cancer Therapies

*Stephen Thorne, Ph.D., Professor and Scientific
Advisor, Inventor, Western Oncolytics*

Oncolytic viruses primarily act as immunotherapies, yet most vectors still rely on the virus' inherent immune activation, often coupled to single cytokine transgene expression. However, for optimal activity they will need to overcome the tumor's immunosuppressive microenvironment, to raise anti-tumor CTL and allow repeated sys-

temic delivery. Approaches to achieve all of these activities in a single vector are being developed.

5:00 End of Day

TUESDAY, AUGUST 30

8:00 am Morning Coffee

TRANSLATIONAL AND CLINICAL UPDATES

8:25 Chairperson's Opening Remarks

8:30 Phase I of Intravenous Vcn-01 in Patients with Advanced Cancer: Update on Clinical & Biologic Data

*Manel Cascallo, Ph.D., Co-Founder,
President and CEO, VCN Biosciences*

A first-in-human Phase I dose escalation study of intravenous administration of VCN-01 (an oncolytic adenovirus with RB tumour-targeting properties and expressing hyaluronidase) with or without gemcitabine and Abraxane is ongoing for patients with advanced solid tumours including pancreatic cancer. Dose dependent tolerability data and VCN-01 levels in different biological samples (including blood and tumour biopsies) are available.

8:50 T-Stealth Technology Mitigates Antagonism between Oncolytic Viruses and the Immune System through Viral Evasion of Anti-Viral T-Cells

Matthew Mulvey, Ph.D., CEO, BeneVir

Simultaneous combination of OV and immune checkpoint inhibitors (ICI) are antagonistic because ICI enhance anti-viral T-cell effector activity and speed OV clearance. BeneVir's T-StealthTM armed OV mitigate antagonism between OV and ICI because they evade anti-viral T-cells. This allows OV and ICI to be administered simultaneously over several treatment cycles to maximize the likelihood of a synergistic clinical response

9:10 Reolsyin: A Clinical Update of a Directed Cytotoxic Agent and Immune Modulator

Brad Thompson, Ph.D., CEO, Oncolytics Biotech

REOLYSIN was initially investigated for its potential as a selective cytotoxin. However, recent research shows that it also functions as an immune modulator. This dual mechanism of action for a single viral

agent suggests that the potential of viral therapies may be broader than previously anticipated.

9:30 Retroviral Replicating Vectors for Cancer-Selective Immuno/Gene Therapy: Translational and Clinical Update

*Noriyuki Kasahara, M.D., Ph.D., Professor,
Departments of Cell Biology and Pathology, Co-
Leader, Viral Oncology Program, University of Miami*

Pro-drug activator gene therapy with retroviral replicating vectors is tumor-selective, and can lead to development of anti-tumor immunity. Ascending dose Phase I trials by Tocagen Inc. in recurrent high-grade glioma demonstrated favorable safety and tolerability, intratumoral virus spread, radiographic responses, and survival surpassing historical benchmarks. Based on these results, a randomized controlled Phase II/III trial is now underway.

10:00 Sponsored Presentations (Opportunities Available)

10:30 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

11:15 Virus Manufacturing Comes of Age: Turning Bugs into Features

*Anthony Davies, Ph.D., COO, 4D
Molecular Therapeutics*

Viruses destroy the host in which you're trying to produce them and then must be separated from all components of those cells. Many solutions to these challenges have been invented since the earliest production of viral vaccines in primary cells obtained directly from animals. But few have proven amenable to cost-effective, compliant and scalable operation.

11:45 Manufacturing Large Enveloped Oncolytic Viruses for Human Clinical Trials

*Mark J. Federspiel, Ph.D., Professor and Director,
Viral Vector Production Laboratory, Mayo Clinic*

The large-scale production and purification of larger enveloped oncolytic viruses are particularly challenging. We have developed enveloped virus GMP production processes using suspension cells in combination with gentle but effective purification using hollow fiber tangential flow filtration that result in greater than 99.5% removal of contaminants and greater than 100-fold increases in final infectious virus titers.

12:15 pm Close of Oncolytic Virus Immunotherapy

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

TUE-WED | AUGUST 30-31



Rational Combination Cancer Immunotherapy

A Forward-Looking View of the Science and Strategies that Will Inform the Discovery and Development of Effective Immunotherapy Combinations

Recommended Dinner Short Course*

Targeting the Cancer Mutanome

*Separate registration required, please see [Short Courses](#) for details

TUESDAY, AUGUST 30

12:00 pm Registration

1:15 Chairperson's Opening Remarks

Arthur M. Krieg, M.D., CEO,
Checkmate Pharmaceuticals

1:20 KEYNOTE PRESENTATION: SELECTING PD-L1/PD-1 IMMUNOTHERAPY COMBINATIONS

Edward Cha, M.D., Ph.D., Associate
Medical Director, Cancer Immunotherapy
Franchise, Genentech

Although targeted inhibition of the PD-L1 pathway enhances anti-tumor immunity, not all patients achieve benefit from single-agent immunotherapies. Determining and prioritizing effective combinations will rely on further understanding of the mechanisms that drive immune resistance across indications and individual patients.

CONSIDERATIONS IN DESIGNING IMMUNOTHERAPY COMBINATIONS

1:50 Rational Combination Immunotherapy Development Stratified by the Presence or Absence of the T Cell-Inflamed Tumor Microenvironment

Jason J. Luke, M.D., FACP, Assistant Professor,
Medicine, Melanoma and Developmental Therapeutics
Clinics, University of Chicago Medical Center

Tumors can be categorized by gene expression based on the presence or absence of a T cell-inflamed tumor microenvironment, and this correlates with either response or lack of response to immune-checkpoint blockade. Categorization of these biologically distinct subsets suggests rational immunotherapy combinations directed toward

either a T cell-inflamed or non-T cell-inflamed tumor microenvironment. This approach also facilitates a framework for interrogating molecular mechanism of immune exclusion mediating non-inflamed tumors.

2:20 Programming DCs *in situ* for Cancer Vaccination

Omar Ali, Ph.D., Staff Scientist, Wyss Institute for
Biologically Inspired Engineering, Harvard University

The innate components required to mediate effective vaccination against weak tumor-associated antigens remain unclear. We utilize three-dimensional and macroporous, polymeric cancer vaccines incorporating different classes of TLR adjuvants to induce tumor regression and protection in order to identify dendritic cell subsets and cytokines critical to this efficacy. Vaccine-induced tumor regression correlated to local CD8(+) DC and pDC numbers, IL-12, and G-CSF concentrations regardless of the incorporated adjuvant.

2:50 Sponsored Presentations (Opportunities Available)

3:20 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 PLENARY KEYNOTE SESSION

See [Keynotes](#) for details.

5:30 Welcome Reception in the Exhibit Hall with Poster Viewing

5:30 Dinner Short Course Registration*

*Separate registration required, please see [Short Courses](#) for details

WEDNESDAY, AUGUST 31

8:00 am Morning Coffee

CLINICAL UPDATES

8:25 Chairperson's Remarks

Christopher R. Heery, M.D., Director,
Clinical Trials Group, Laboratory of Tumor
Immunology, Center for Cancer Research

8:30 Breaking the Suppressive Myeloid Barrier to Overcome Checkpoint Blockade Resistance

Michael A. Curran, Ph.D., Assistant Professor,
Immunology; Scientific Director, ORBIT
Platform MD Anderson Cancer Center

While blockade of T cell immune checkpoint molecules such as CTLA-4 and PD-1 has dramatically improved therapeutic outcomes in metastatic melanoma and lung cancer, many other cancers such as those of the pancreas, prostate, and colon (MSI-low) fail to respond. We find that suppressive myeloid cells play a critical role in mediating this resistance, and that through their disruption these cancers can be sensitized to checkpoint blockade.

9:00 Novel Combinations of Immunotherapeutics Based on Preclinical Modeling and Clinical Biomarker Analysis

Christopher R. Heery, M.D., Director,
Clinical Trials Group, Laboratory of Tumor
Immunology, Center for Cancer Research

This talk will discuss examples of clinical trial design based on integration of preclinical modeling and pharmacokinetic and pharmacodynamic analysis of early stage trials. The focus will be on integration of new findings as an iterative process toward optimal trial design to achieve maximal clinical benefit.

9:30 FEATURED PRESENTATION: SUMMARY OF KEY CLINICAL COMBINATION TRIALS PRESENTED AT ASCO

Paul Rennert, Ph.D., President &
CSO, Aleta Biotherapeutics Inc.

ASCO 2016 will give us new insights into diverse and interesting advances in oncology therapeutics. I will report on the top studies of interest in the following areas: novel immune checkpoints and checkpoint combinations; immune checkpoint combinations with other therapies, targets in the tumor microenvironment, CAR T and TCR therapies, and other studies that enrich our understanding of immuno-oncology as a broad-based discipline for cancer therapy.

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

10:00 Sponsored Presentations
(Opportunities Available)

10:30 Coffee Break in the Exhibit Hall with Poster Viewing

11:15 Cancer Immunotherapy: Immunomodulatory Approaches Beyond PD-1

Andrea van Elsas, Ph.D., CSO, Aduro Biotech Europe, The Netherlands

T cell checkpoint inhibitors set a clinical paradigm providing significant benefit to patients diagnosed with advanced cancer. Despite success, the majority of patients do not respond to PD-1, PD-L1 or CTLA-4 blockade. Raising the number of patients benefiting from cancer immunotherapy requires novel therapeutic approaches aimed at these non-responders, for instance using novel immunomodulatory antibodies and combination with active immunization.

11:45 Panel Discussion: Best Practices for Organizations and Academic Labs Entering the Cancer Immunotherapy Space

Moderator: Llew Keltner, M.D., Ph.D., CEO, EPISTAT

The scientific potential of immunotherapy combinations is vast, and the clinical successes in this space have attracted significant numbers of large and small players to the field. Our panel will dissect the most important scientific and strategic considerations for those wanting to participate in these collaborations and offer audience members the opportunity for focused feedback from experts in business, regulatory, scientific, healthcare and dealmaking functions.

Panelists:

Konstantin M. Linnik, Ph.D., Partner, Intellectual Property, Nutter, McClennen & Fish, LLP

Kuldeep Neote, Ph.D., Senior Director, New Ventures, J&J Innovation Center Boston

Taylor Schreiber, M.D., Ph.D., CSO, Heat Biologics, Inc.

Elena Spanjaard, Ph.D., Director, Worldwide Research & Development, Regulatory Affairs, Pfizer

12:45 pm Luncheon Presentation
(Sponsorship Opportunity Available)
or Enjoy Lunch on Your Own

1:15 Session Break

IMMUNOTHERAPY COMBINATION STRATEGIES

1:55 Chairperson's Remarks

Paul Rennert, Ph.D., President & CSO, Aleta Biotherapeutics Inc.

2:00 Next-Generation Biomarkers for the Era of Combination Cancer Immunotherapy

David Kaufman, Ph.D., Executive Director, Clinical Oncology, Merck Research Laboratories

A variety of other agents may have additive or synergistic activity in combination with PD-1 checkpoint blockade. As such regimens advance, it will be critically important to understand how to direct the right combinations to patients who stand to benefit most from them. Next-generation biomarkers are beginning to provide insight into fundamental aspects of tumor cell and immune biology that are relevant for a precision medicine approach to cancer immunotherapy combinations.

2:30 Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma

Patrick Alexander Ott, M.D., Ph.D., Assistant Professor, Medicine, Dana-Farber Cancer Institute

Emerging evidence indicates that immunotherapy can lead to immune-mediated vasculopathy in the tumor. While the inhibition of angiogenesis through targeting of vascular endothelial growth factor (VEGF) has been used successfully for the treatment of cancer the mechanisms of its anti-tumor activity remain poorly understood. Initial studies of the complex relationship between angiogenesis, VEGF signaling and the immune system suggest that the combination of immune checkpoint blockade with angiogenesis inhibition has potential.

3:00 Rationale for Combinatorial Immunotherapy Approaches

Chris Boshoff, M.D., Ph.D., Vice President and Head, Early Development, Translational and Immuno-Oncology, Pfizer

Immunotherapy is poised to become an integral part of the cancer treatment paradigm. Cytotoxics, TKIs, other small molecules, and non-IO large molecules like ADCs will remain important treatment modalities. Understanding how these could be combined or sequenced with immunotherapy to transform cancer care is crucial. Pfizer's immunotherapies in the clinic include those targeting PD-1, PD-L1, CTLA-4, OX-40, CD137, CCR2, and MSCF. The rationale for combinatorial strategies will be discussed.

3:30 Refreshment Break with Exhibit and Poster Viewing

4:15 Immunotherapy in Combination with Novel Tumor Vaccines

Craig L. Slingluff, Jr., M.D., Professor, Surgery, University of Virginia School of Medicine

New approaches to cancer vaccines may use neoantigens, novel antigen formulations, or modified delivery systems. Promising findings support vaccines targeting CD4+ helper T cells, and new approaches to in situ vaccination show promise. Novel vaccine adjuvants may augment T cell responses, and combinations with a range of checkpoint blockade molecules or other systemic therapy agents may favorably modulate immune responses to vaccines and to human cancers.

4:45 Novel Combination Immunotherapy Strategies to Optimize T Cell Responses Against Cancer

Howard L. Kaufman, M.D., FACS, Associate Director, Clinical Science, Chief Surgical Officer, Rutgers Cancer Institute of New Jersey

The remarkable success of T cell checkpoint inhibitors has highlighted the importance of promoting activation and preventing suppression of T cells for the treatment of cancer. This presentation will discuss the central importance of T cells within the tumor microenvironment, highlight some of the more promising combinations in development and provide recommendations for how to select the most promising immunotherapy agents for combination regimens.

5:15 Enhancing the Efficacy of Checkpoint Inhibition with a TLR9 Agonist Delivered in a Virus-Like Particle

Arthur M. Krieg, M.D. CEO, Checkmate Pharmaceuticals

Checkpoint inhibitors can induce durable remissions in patients with advanced malignancies that are immunologically "hot" (have a type I IFN signature and CD8 T cell infiltrates) but they are rarely effective in the treatment of immunologically "cold" tumors. Intratumoral injection of a TLR9 agonist CpG-A oligonucleotide is expected to convert "cold", checkpoint-unresponsive tumors into "hot" tumors, resulting in an increased response rate to combination therapy.

5:30 Dinner Short Course Registration

5:45 Close of Rational Combination Cancer Immunotherapy

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
InformationRegistration
InformationClick Here to
Register Online!
Immuno-Oncology
Summit.com

250 First Avenue
Needham, MA 02494
www.healthtech.com

TUE-WED | AUGUST 30-31



Personalized Immunotherapy

Personalized Oncology in the Genomic Era: Expanding the Druggable Space

Recommended Dinner Short Course*

Bisppecific Antibody Development for Immunotherapy

*Separate registration required, please see [Short Courses](#) for details

TUESDAY, AUGUST 30

12:00 pm Registration

TUMOR NEOANTIGENS FOR PERSONALIZED IMMUNOTHERAPY

1:15 Chairperson's Opening Remarks

Pramod K. Srivastava, M.D., Ph.D., Professor, Immunology and Medicine, Director, Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine

1:20 Basics of Personalized Immunotherapy: What Is a Good Antigen?

Pramod K. Srivastava, M.D., Ph.D., Professor, Immunology and Medicine, Director, Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
The definition of host-protective immunogenic antigen(s) of any human cancer of non-viral origin is still an enigma. New approaches in cancer genomics and bioinformatics are now offering a plethora of candidate antigens, whose role in cancer immunity, and specifically in host-protective cancer immunity, is under extensive testing. Outlines of some broad rules are emerging and some of these shall be discussed.

1:50 Novel Antibodies against Immunogenic Neoantigens

Philip M. Arlen, M.D., President & CEO, Precision Biologics, Inc.

Two novel antibodies, NEO-102 (ensituximab) and NEO-201, were developed from an allogeneic colorectal cancer vaccine that had previously shown activity in patients with metastatic colorectal cancer. This vaccine was derived from an immunogenic component of the cell membrane from pooled surgical specimens from both primary and metastatic colon cancer. Patients who benefited from the vaccine in the prior clinical trial produced and sustained high levels of serum IgG against the vaccine. Several thousand candidate antibodies

were screened against this vaccine and NEO-102 and NEO-201 were candidates that demonstrated the ability to bind to colon cancer vs. normal tissue.

2:20 PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Luis Alberto Diaz, M.D., Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Somatic mutations have the potential to encode "non-self" immunogenic antigens. Tumors with a large number of somatic mutations due to mismatch-repair defects appear to be highly susceptible to immune checkpoint blockade. This presentation will summarize the clinical and genomic data of using mutations as neoantigens.

2:50 Sponsored Presentations (Opportunities Available)

3:20 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 PLENARY KEYNOTE SESSION

See [Keynotes](#) for details.

5:30 Welcome Reception in the Exhibit Hall with Poster Viewing

5:30 Dinner Short Course Registration*

*Separate registration required, please see [Short Courses](#) for details

WEDNESDAY, AUGUST 31

8:00 am Morning Coffee

PERSONALIZED IMMUNOTHERAPY WITH CANCER VACCINES

8:25 Chairperson's Remarks

Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health

8:30 Cancer Vaccines in the Era of Checkpoint Inhibitors

Keith L. Knutson, Ph.D., Professor, Immunology, Mayo Clinic

Vaccination has been one of the most successful approaches to reduce incidence and mortality rates of infectious diseases and more recently cancer, including cervical cancer. Our goal is to develop vaccine strategies that can be delivered to breast cancer patients to boost host immune defenses following conventional treatments (e.g., surgery, chemotherapy, and radiation), in order to prevent recurrence of treatment resistant tumors. We believe that one of the better approaches is to vaccinate against abnormally expressed 'self' (non-mutated) antigens that contribute to the cancer initiation and progression.

9:00 Developing Therapeutic Cancer Vaccine Strategies for Prostate Cancer

Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health

The development of immunotherapy strategies has become the primary focus in oncology. This lecture will provide prostate cancer as a template to demonstrate synergies between immune-based therapies and chemotherapy, radiopharmaceuticals and hormonal therapies.

9:30 Getting Very Personal: Fully Individualized Tumor Neoantigen-Based Vaccine Approaches to Cancer Therapy

Karin Jooss, Ph.D., CSO, Gritstone Oncology

Genetic instability in tumors generates tumor-specific neoantigens which have been identified as the targets of new T cells in patients responding to checkpoint inhibitor therapy. Predicting neoantigens by sequencing routine clinical biopsy material, and then incorporating them into therapeutic cancer vaccines is an attractive concept being developed by Gritstone Oncology. The complexities of neoantigen prediction will be discussed, together with insights into how vaccine vectors are selected and designed.

10:00 Presentation to be Announced

10:15 Sponsored Presentation (Opportunity Available)

Sponsored by:



10:30 Coffee Break in the Exhibit Hall with Poster Viewing

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

11:15 *In situ* Vaccination for Lymphoma

Joshua Brody, M.D., Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai

Prior *ex vivo* combinations of dendritic cells (DC) with tumor antigens have yielded immunologic and clinical responses. Intratumoral immunomodulation may bypass the need for *ex vivo* production of vaccine. *In situ* vaccination combines: intratumoral Flt3L to recruit DC, low dose radiotherapy to load DC with tumor antigens, and intratumoral TLR agonist to activate tumor-antigen-loaded DC. Preliminary results demonstrate DC recruitment and activation, systemic tumor regressions, and induction of neoantigen specific CD8 T cell responses after vaccination.

11:45 Immunotherapy Using Ad5 [E1-, E2b-] Vector Vaccines in the Cancer MoonShot 2020 Program

Frank R. Jones, Ph.D., Chairman & CEO, Etubics Corporation

The Cancer MoonShot 2020 project intends to design, initiate and complete randomized clinical trials at all stages of cancer in up to 20 tumor types in as many as 20,000 patients by the year 2020. Etubics is participating in the Cancer MoonShot 2020 program by providing its proprietary viral platform, known as Ad5 [E1-, E2b-] as a treatment agent in several of the program's immunotherapeutic vaccination initiatives and trials.

12:15 pm Sponsored Presentations (Opportunities Available)

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Session Break

PERSONALIZED CELL THERAPY

1:55 Chairperson's Remarks

Andrew M. Evens, D.O., Professor and Chief, Hematology/Oncology, Tufts University School of Medicine; Director, Tufts Cancer Center

2:00 Integration of Natural Killer-Based Therapy into the Treatment of Lymphoma

Andrew M. Evens, D.O., Professor and Chief, Hematology/Oncology, Tufts University School of Medicine; Director, Tufts Cancer Center

Targeting signaling pathways or epitopes with small molecules and antibody-based immunotherapeutic agents is a leading strategy for cancer therapy. Promising immunotherapy agents being

examined for the treatment of lymphoma include monoclonal antibodies, immunomodulatory agents, PD-1 inhibitors, chimeric antigen receptor (CAR) T-cells, and NK-based therapies. The optimum combinations or sequences of these therapeutics continue to be defined. Additionally, understanding tumor and patient/host heterogeneity is desired in order to optimize personalized medicine.

2:30 Dendritic Cells: Personalized Cancer Vaccines and Inducers of Multi-Epitope-Specific T Cells for Adoptive Cell Therapy

Pawel Kalinski, M.D., Ph.D., Professor, Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute

Conditions of dendritic cell (DC) maturation affect their ability to cross-present cancer cell-derived antigens and induce clonal expansion and effector functions of responding T cells. We will discuss the pathways of DC maturation which promote their preferential interaction with naïve, memory and effector T cells, cross-presentation of antigens from dead cancer cells, and induction of large numbers of type-1 CD4+ and CD8+ T cells specific for multiple tumor-associated antigens *ex vivo* and *in vivo*.

3:00 Mesothelin-Targeted CAR T-Cell Therapy for Solid Tumors

Prasad S. Adusumilli, M.D., FACS, Deputy Chief of Translational & Clinical Research, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center
Mesothelin, a cell-surface antigen, provides an exciting prospect based on its higher expression in a majority of solid tumors (estimated annual incidence of 340,000 and prevalence of 2 million patients in the U.S.), limited expression in normal tissues and its association with tumor aggressiveness. CAR T-cell therapy with second generation mesothelin-targeted CARs has been translated to clinical trials targeting mesothelioma, non-small cell lung cancer, triple-negative breast cancer, and other solid tumors.

3:30 Refreshment Break with Exhibit and Poster Viewing

4:15 Synthetic Regulation of T Cell Therapies Adds Safety and Enhanced Efficacy to Previously Unpredicted Therapies

David M. Spencer, Ph.D., CSO, Bellicum Pharmaceuticals

CAR- and TCR-based T cell therapies have had some spectacular successes in a handful of malignancies, but safety and efficacy

concerns still impede broader adoption of these new technologies. Bellicum Pharmaceuticals has developed a suite of synthetic ligand-inducible switches to rapidly and rigorously regulate T cell therapies. These potent switches address both safety and anti-tumor efficacy and promise to further expand the reach of immunotherapy.

4:45 Long-Term Relapse-Free Survival of Patients with Acute Myeloid Leukemia (AML) Receiving a Telomerase- Engineered Dendritic Cell Immunotherapy

Jane Lebkowski, Ph.D., President & CSO, Research and Development, Asterias Biotherapeutics

There are few treatment options for patients with intermediate and high risk AML, and remission and relapse rates are dismal, especially in patients ≥ 60 years old. A Phase II clinical trial was conducted in subjects with AML to assess a dendritic cell immunotherapy (ASTVAC1) engineered to express a modified form of telomerase that is processed through both the MHC Class I and II antigen presentation pathways. The results suggest that immunotherapy with AST-VAC1 is safe, can stimulate immune responses to telomerase, and may extend relapse-free survival even in patients with high risk AML.

5:15 Activated and Exhausted Tumor Infiltrating B Cells in Non-Small Cell Lung Cancer Patients Present Antigen and Influence the Phenotype of CD4 Tumor Infiltrating T Cells

Tullia Bruno, Ph.D., Research Assistant Professor, Immunology, University of Pittsburgh

The focus of immunotherapy has been on subsets of CD8 and CD4 tumor infiltrating lymphocytes (TILs), however, tumor infiltrating B cells (TIL-Bs) have been reported in tertiary lymphoid structures (TLS) with CD4 TILs, and both TIL-Bs and TLS correlate with NSCLC patient survival. While TIL-Bs have been identified in NSCLC patients, their function in the tumor microenvironment has been understudied with no focus on their role as antigen presenting cells (APCs) and their influence on CD8 and CD4 TILs. Here, we demonstrate that TIL-Bs can efficiently present antigen to CD4 TILs and influence CD4 TIL phenotype depending on their exhaustion profile.

5:30 Dinner Short Course Registration

5:45 Close of Personalized Immunotherapy Conference

Cover

Conference-at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit Opportunities

Training Seminar

Agenda

Hotel & Travel Information

Registration Information

Click Here to Register Online!
Immuno-Oncology Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

TUE-WED | AUGUST 30-31



Preclinical & Translational Immuno-Oncology

Predictive Preclinical Models for Cancer Immunotherapy

Recommended Dinner Short Course*

Bisppecific Antibody Development for Immunotherapy

*Separate registration required, please see [Short Courses](#) for details

TUESDAY, AUGUST 30

12:00 pm Registration

PRECLINICAL MODELS FOR IMMUNO-ONCOLOGY

1:15 Chairperson's Opening Remarks

Douglas Linn, Ph.D., Senior Scientist, In Vivo Pharmacology, Merck

1:20 Development of Therapeutic Antibodies to Immune Checkpoint Receptors and Their Validation in Humanized Mice

Ella Ioffe, Ph.D., Associate Director, Immune-Oncology, Regeneron Pharmaceuticals

PD-1 and LAG-3 are immune checkpoint receptors on effector T cells, which when activated can allow tumors to escape immunosurveillance. Regeneron has generated fully human monoclonal antibodies that block (human) PD-1 and LAG-3 function. However, since these antibodies do not block murine proteins, we engineered mice expressing humanized ectodomains of PD-1 and LAG-3 from the murine loci, to allow *in vivo* testing of these clinical antibodies. Robust anti-tumor efficacy of anti-PD-1 (REGN2810) and anti-LAG-3 in humanized mice supports their clinical development in combination cancer immunotherapy.

1:50 Applying Preclinical Immuno-Oncology Mouse Models to Guide Decisions in the Clinic

Douglas Linn, Ph.D., Senior Scientist, In Vivo Pharmacology, Merck

The success of immunotherapies such as checkpoint inhibitors has changed the way cancers are being treated. Preclinical immuno-oncology mouse models provide tremendous value to shaping clinical strategies given that countless potential combinations exist with other immunotherapies, radiation, and/or standards of care. This talk will provide an overview of how immuno-oncology mouse models serve a critical role in guiding treatment options at the bedside.

2:20 Understanding the Tumor Microenvironment: Insights from Studying Mouse Tumor Models

Zhao Chen, Ph.D., Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

The success of cancer immunotherapy brings our attention to the non-tumor components of cancer. The cross-talks between different cell populations within the tumor microenvironment (TME) likely dictate the efficiency and efficacy of anti-tumor immune response. Yet, what governs the immune system status within a given tumor remains unclear. Using mouse cancer models, we are able to address specific questions including the roles of tumor genotypes and tumor location in shaping up TME.

2:50 Sponsored Presentations (Opportunities Available)

3:20 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 PLENARY KEYNOTE SESSION

See [Keynotes](#) for details

5:30 Welcome Reception in the Exhibit Hall with Poster Viewing

5:30 Dinner Short Course Registration*

*Separate registration required, please see [Short Courses](#) for details

WEDNESDAY, AUGUST 31

8:00 am Morning Coffee

TRANSLATIONAL RESEARCH ON COMBINATIONAL IMMUNOTHERAPY

8:25 Chairperson's Remarks

Oliver Ghobrial, Ph.D., Principal Scientist, Translational Informatics, Sanofi

8:30 Augmenting Anti-Tumor Immune Response by Targeting the Notch or Wnt Pathways in Combination with PD1 Axis Blockade

Jakob Dupont, M.D., Senior Vice President & CMO, OncoMed Pharmaceuticals

9:00 Translational Research Using an *in silico* QSP (Quantitative Systems Pharmacology) Immuno-Oncology Platform Model

Oliver Ghobrial, Ph.D., Principal Scientist, Translational Informatics, sanofi Grp

Research supports the premise that cancer patients are likely to benefit from treatment with combinations of immune-therapy modalities as well as with classical chemotherapeutic approaches. Quantitative understating of the potential synergistic vs. conflicting approaches, given the immunosuppressive effects of some anticancer methodologies, is key to selection of the optimal combination. QSP holds promise to enable an understanding of the target interactions as it relates to the biological systems underlying disease, thus enabling an informed selection of the treatment modalities as well as the optimal dose and regimen.

9:30 A Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy

Rodney Prell, Ph.D., DABT, Principal Scientist/ Toxicologist, Safety Assessment, Genentech

The tumor microenvironment establishes several inhibitory pathways that lead to suppression of the local immune response, which is permissive for growth. Similar pathways have also evolved during pregnancy as a way to protect the fetus from immune-mediated rejection. Therefore, cancer immunotherapies designed to enhance the immune response against the tumor may have the undesired effect of increasing immune responses to allo-antigens expressed by the fetus. Reproductive toxicity studies are meant to reveal any potential effects on mammalian reproduction at various stages and are used to inform the potential risk to women that are or may become pregnant, while receiving treatment.

10:00 Understanding the Impact of Animal Vendors and the Microbiome—in Tumor Progression and Treatment—in a Model of Metastatic Breast Cancer

Britnie James, Ph.D., Lead Scientist, Research & Development, MD Biosciences

Dysbiosis can correlate with the predisposition and progression of cancer. Animal vendor differences in the microbiome can impact immunological and cellular functions. We have examined whether animals from different vendors, with discrete microbiomes, would present with differ-

Sponsored by:
mdbiosciences.

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

ent disease progression and therapy responses in a murine model of metastatic breast cancer.

10:30 Coffee Break in the Exhibit Hall with Poster Viewing

NOVEL *IN VITRO* MODELS FOR IMMUNOTHERAPY DISCOVERY

11:15 Lead Selection and Validation of Immunotherapy Combinations on TILs

Cokey Nguyen, Ph.D., Vice President, R&D, Enumeral

Typical antibody discovery processes follow a screening funnel of activities that focus on biochemical parameters such as affinity and epitope mapping prior to determining cell-based assay activity. This paradigm is particularly challenging in the field of immune-oncology because assessing antibody activity on cell lines or human peripheral mononuclear cells may not predict activity in the tumor microenvironment. We describe here a screening paradigm that assesses cell-based assay activity on primary TILs early.

11:45 Testing Efficacy of Immunotherapy *in vitro*: Primary 3D Co-Cultures of Tumor Cells and T Lymphocytes

Christian Schmees, Ph.D., Head of Tumor Biology, Molecular Biology Department, NMI Natural and Medical Sciences Institute at the University of Tübingen

The development of more efficient approaches in cancer immunotherapy necessitates the application of cellular models closely resembling patient tumors. In my talk, I will present data derived from a patient-derived model system involving the co-culture of 3D tumor spheroids and T lymphocytes. Imaging-based analyses of these models allow for the evaluation of T lymphocyte infiltration as well as T cell induced cytotoxicity in the spheroids in response to antigen stimulation and/or compound treatment.

12:15 pm Tipping the Balance: Overriding Phosphatidylserine-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies

Bruce Freimark, Ph.D., Research Director, Preclinical Oncology, Peregrine Pharmaceuticals

Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals which contribute to an immunosuppressive environment. Antibody blockade of PS activates immune responses by promoting M1 macrophages, maturation of dendritic cells and inducing adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity and survival of checkpoint antibodies in preclinical tumor models by increasing activated cytotoxic T-cell infiltrates and immune stimulatory mediators.

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Session Break

NEW TARGETS FOR CHECKPOINT INHIBITORS

1:55 Chairperson's Remarks

Xingxing Zang, Ph.D., Associate Professor, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine

2:00 Tumor Associated Myeloid Cells Can Be Rendered Dysfunctional by the Tumor Microenvironment through Expression of TIM-3: Implications for TIM-3 Blockade in Cancer

Pushpa Jayaraman, Ph.D., Investigator II, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

TIM-3, a T cell exhaustion marker, is more dominant on myeloid cells than on T cells in murine syngeneic tumor models and in renal cell carcinoma (RCC) treatment-naïve patients. We present data that TIM-3+ myeloid cells are dysfunctional, and that TIM-3 blockade rescues myeloid pro-inflammatory function. The pathophysiological role of the TIM-3 pathway in innate immunity might have important consequences on T cell function and TIM-3 blockade in cancer.

2:30 New Targets for Human Cancer Immunotherapy

Xingxing Zang, Ph.D., Associate Professor, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine

CTLA-4 and the PD-1/PD-L1 pathway are current focuses for cancer immunotherapy. This presentation will discuss other new immune checkpoints for future human cancer immunotherapy.

3:00 Modulating Interferon-Gamma Induced PD-L1 Expression in Medulloblastoma

Alex Yee-Chen Huang, M.D., Ph.D., Associate Professor, Pediatrics, Pathology & Biomedical Engineering, Case Western Reserve University School of Medicine

Tumors up-regulate immune checkpoint molecules, including PD-L1, in response to immune effector cytokines such as interferon-gamma. Recent data have revealed new molecular target(s), the interference of which can modulate PD-L1 expression by medulloblastoma in response to interferon-gamma, and can result in efficient tumor elimination by normal host immune response. These exciting findings and their clinical implications will be discussed.

3:30 Refreshment Break with Exhibit and Poster Viewing

PATHWAY DISCOVERY FOR COMBINATION THERAPY

4:15 ICOS Signaling Promotes CD4+ Effector T Cell Function during Anti-Tumor Immune Responses

Todd Metzger, Ph.D., Senior Scientist, Cancer Immunology, Pfizer

ICOS provides an important costimulatory signal to T cells during activation, but its role within the tumor microenvironment is unclear. We have generated an anti-ICOS-L antibody which reveals a requirement for ICOS signaling to maintain the function of multiple T cell subsets within the tumor. Additionally, we find that anti-OX40 therapies promote ICOS expression, and that co-targeting of the OX40 and ICOS pathways supports enhanced anti-tumor immune responses.

4:45 Immune Modulation: Targets beyond CTLA-4/PD-1 Axes

Catherine Sabatos-Peyton, Ph.D., Senior Investigator, Novartis Institutes for BioMedical Research

With the proven clinical efficacy of PD-1/PD-L1 and CTLA-4 agents in multiple cancer indications, immunotherapy has come to the forefront as a way to modulate an anti-tumor response. Beyond the PD-1/PD-L1 axis, multiple other checkpoint inhibitors, including LAG-3 and TIM-3, have moved into the clinic and distinct modalities may lead to synergistic anti-tumor effects with PD-1 pathway co-blockade. Coordinated modulation of the tumor microenvironment by relieving suppressive pathways to favor CD8+ effector T cell activation may open avenues to broader applicability of immunotherapy in cancer.

5:15 Of Mice and Men: Translating the Immune Oncology Mechanism of Action of NKTR-214

Jonathan Zalevsky, Ph.D., Vice President, Biology & Preclinical Development, Nektar Therapeutics

NKTR-214, a CD122-biased immune-stimulatory cytokine, is designed to expand the numbers and activity of tumor-killing lymphocytes and has shown promising preclinical results as a single agent and in combination with checkpoint inhibitors, cell-therapies, and vaccines. In the Phase I/II clinical study, translational research will assess the immunologic effect of NKTR-214 on tumor-infiltrating lymphocytes (TILs) and other immune cells in both blood and serial tumor biopsies to identify potential biomarkers.

5:30 Dinner Short Course Registration

5:45 Close of Preclinical and Translational Immuno-Oncology Conference

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
InformationRegistration
InformationClick Here to
Register Online!
Immuno-Oncology
Summit.com

250 First Avenue
Needham, MA 02494
www.healthtech.com



Adoptive T Cell Therapy

Delivering CAR, TCR, and TIL from Research to Reality

Recommended Dinner Short Course*

Adoptive Therapy With CAR T Cells

*Separate registration required, please see [Short Courses](#) for details

THURSDAY, SEPTEMBER 1

7:45 am Registration & Morning Coffee

PRINCIPALS OF ENGINEERED RECEPTOR DESIGN

8:25 Chairperson's Opening Remarks

Adrian Bot, M.D., Ph.D., Vice President,
Translational Sciences, R&D, Kite Pharma Inc.

8:30 KEYNOTE PRESENTATION: CLINICAL DEVELOPMENT OF TUMOR-INFILTRATING LYMPHOCYTE THERAPY FOR SOLID TUMORS: THE MYTHS AND THE REALITY

Laszlo Radvanyi, Ph.D., Senior Vice President and
Head, Immuno-
Oncology Translational Innova-
tion Platform (TIP), EMD Serono

Many of the patients treated with TILs have progressed after multiple therapies, including checkpoint blockade with anti-CTLA-4 and anti-PD-1/PD-L1, making TIL also an ultimate salvage therapy option. In this presentation, we will discuss common misconceptions about TIL therapy and current efforts that can realistically bring TIL therapy into the mainstream as an approved product for melanoma care as well as its promise as a cellular therapy for other solid cancers.

9:00 Engineering Better T Cells

Daniel Williams, Head, UK Research
Operations, Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company developing engineered TCRs for adoptive T cell therapy. Engineering TCRs specific for tumor antigens which are self-antigens, requires balancing

the need for increasing affinity to the target peptide to allow recognition of immune-selected tumors, with the risk of cross-reactivity, which increases at higher affinities. Target identification and validation, together with a broad and robust preclinical safety testing strategy are critical in the development of safe and efficacious affinity-enhanced TCRs.

9:30 Development of an Anti-BCMA Specific CAR with Potent Anti-Multiple Myeloma Activity

Richard A. Morgan, Vice President,
Immunotherapy, bluebird bio

B cell maturation antigen (BCMA) is expressed on most multiple myeloma (MM) cells, yet normal tissue expression is limited to plasma and some B cells. Here we demonstrate that a potent, antigen-dependent, memory-like BCMA CAR T cells can be produced with a scalable manufacturing process that mediated robust tumor regressions in animal models. A Phase I clinical trial to test this approach in patients with relapse refractor MM is underway.

10:00 Coffee Break with Exhibit and Poster Viewing

TARGETS FOR T CELL INTERVENTIONS

10:45 CD19 as a Prototypic B Cell Lineage Target for CAR T Cells

Adrian Bot, M.D., Ph.D., Vice President,
Translational Sciences, R&D, Kite Pharma Inc.

Anti-CD19 CAR T cells could be the first marketed products in this space. Prolonged B cell deficiency may not be desirable since B cells are required to combat major pathogens. Product candidates capable to mediate rapid and profound tumor debulking, can yield durable clinical responses without persisting B cell deficiency. Novel evidence will be presented, linking product characteristics, conditioning, and biomarkers, to the clinical outcome afforded by CAR T cells.

11:15 CAR-T Cells for Hematological Malignancies: Exploring Alternative Targets

Gianpietro Dotti, M.D., Professor, Microbiology
and Immunology, University of North Carolina

Adoptive transfer of CD19-specific CAR-T cells showed remarkable anti-tumor activity in patients with B-cell derived acute lymphoblastic leukemia and lymphomas. Alternative targets have been explored in Phase I studies in hematological malignancies. Specifically, in the effort to reduce the B cell aplasia associated with effective and long-term persisting CD19-specific CAR T cells, we implemented at Baylor College of Medicine a Phase I study with CAR-T cells targeting the k-light chain of human immunoglobulin to selectively eliminate k+ tumors whilst sparing normal I+ B lymphocytes. To target Hodgkin's Lymphoma and other CD30+ lymphomas, we also implemented a Phase I study with CAR-T cells targeting the CD30 antigen. Outcome of these studies and future directions will be reported.

11:45 PANEL: CAR T Cell Therapy: Target Antigen Discovery and Clinical Translation

Panelists: Adrian Bot, M.D., Ph.D., Vice President,
Translational Sciences, R&D, Kite Pharma Inc.

Gianpietro Dotti, M.D., Professor, Microbiology
and Immunology, University of North Carolina

Richard A. Morgan, Vice President,
Immunotherapy, bluebird bio

- Market potential of anti-CD19 CAR T Cells
- The latest clinical results
- Scalability and manufacturing challenges
- Future directions for CAR therapies

12:15 pm Sponsored Presentations (Opportunities Available)

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Session Break

2:00 Chairperson's Remarks

Adrian Bot, M.D., Ph.D., Vice President,
Translational Sciences, R&D, Kite Pharma Inc.

Cover

Conference-at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit Opportunities

Training Seminar

Agenda

Hotel & Travel Information

Registration Information

Click Here to Register Online!
Immuno-Oncology Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

2:05 Human Papillomavirus (HPV)-Targeted T Cells for HPV-Associated Cancers

Christian S. Hinrichs, M.D., Investigator, Experimental Transplantation and Immunology Branch, Lasker Clinical Research Scholar, NIH

Human papillomavirus (HPV) causes cancers of the uterine cervix, oropharynx, anus, vulva, vagina and penis. These cancers express the HPV E6 and E7 oncoproteins, which are attractive immunotherapeutic targets. Recent work has sought to target these antigens using tumor-infiltrating lymphocytes and genetically engineered T cells.

2:35 XPRESIDENT®-Guided Target Identification and Profiling of On-and Off-Target Toxicity for Safer Adoptive Cell Therapy

Steffen Walter, Ph.D., CSO, Immatics Biotechnologies GmbH

A major constraint for the broad and safe application of Adoptive Cellular Therapy is the limited number of validated tumor targets and TCRs. We used a proprietary target discovery engine (XPRESIDENT®) combining highly sensitive quantitative mass spectrometry, transcriptomics, immunology and bioinformatics to characterize the immunopeptidome directly on human normal and tumor tissues. We show how this approach can be used to predict on- and off-target toxicities in TCR-based immunotherapies.

3:05 Sponsored Presentations (Opportunities Available)

3:35 Refreshment Break

4:05 Engineering Designer T Cells for Immunotherapy

Wolfgang Uckert, Associate Professor, Department of Cell Biology and Gene Therapy, Humboldt University Berlin

Successful immunotherapy using T cell receptor (TCR) gene-modified T cells to treat cancer, viral infections or autoimmune diseases is depending on the careful selection of: (i) the target antigen, (ii) a TCR with optimal affinity, (iii) an efficient gene delivery system, and (iv) a safety switch to interrupt therapy in case of severe adverse side effects. Examples of these different areas to generate designer T cells for successful TCR gene therapy are given and discussed.

4:35 KEYNOTE PRESENTATION: A COMPARISON OF TCRs AND CARs: SENSITIVITIES AND SPECIFICITIES

David M. Kranz, Phillip A. Sharp Professor, Biochemistry, University of Illinois, Urbana-Champaign

T cells, via their T-cell receptors (TCRs), evolved to target intracellular peptides as low-density, cell-surface complexes with MHC products. Synthetic constructs known as chimeric antigen receptors (CARs) contain an anti-tumor antigen scFv and recognize higher density antigens. We have designed high-affinity human TCRs in conventional heterodimer format and in CAR-like formats to directly compare features of both systems. These features include T cell surface levels, antigen sensitivities and other properties.

5:05 PANEL: Designing T Cells for Immunotherapies

Panelists:

Christian S. Hinrichs, M.D., Investigator, Experimental Transplantation and Immunology Branch, Lasker Clinical Research Scholar, NIH
Steffen Walter, Ph.D., CSO, Immatics Biotechnologies GmbH

Wolfgang Uckert, Ph.D., Associate Professor, Cell Biology and Gene Therapy, Humboldt University Berlin
David M. Kranz, Phillip A. Sharp Professor, Biochemistry, Biochemistry, University of Illinois

- Strategies for antigen selection and targeting
- Increasing sensitivity and specificities
- Utilizing efficient gene delivery systems
- Dealing with toxicities

5:05 Dinner Short Course Registration*

*See [Short Courses](#) for details

5:35 End of Day

FRIDAY, SEPTEMBER 2

8:00 am Morning Coffee

TARGETING SOLID TUMORS

8:25 Chairperson's Opening Remarks

Armon Sharei, Ph.D., CEO, SQZ Biotechnologies

8:30 Vector-Free Engineering of Immune Cells for Enhanced Antigen Presentation

Armon Sharei, Ph.D., CEO, SQZ Biotechnologies

Robust engineering of immune cell function is critical to realizing the therapeutic potential of cell therapies in cancer. Our vector-free CellSqueeze technology has demonstrated novel capabilities in diverse areas including engineering antigen presentation to drive powerful and significant T-cell responses. We will present recent developments in our cell-based immunotherapy programs aimed at using patient-derived antigens to target a variety of cancer indications, including solid tumors.

9:00 Design of a Highly Efficacious CAR Targeting Mesothelin in Solid Tumors

Boris Engels, Ph.D., Investigator, Exploratory Immunology, Novartis Institutes for Biomedical Research

The treatment of solid tumors with CAR T cells remains challenging. We describe the design of a human CAR targeting mesothelin, a tumor associated antigen overexpressed in many cancers. A pooled screen identified scFvs, which show enhanced efficacy, superior to the CARs currently used in the clinic. We performed in-depth characterization of the scFvs and CARs to gain insight into structure-activity relationships, which may influence CAR efficacy and future design.

9:30 Overcoming CAR T Cell Checkpoint Blockade in Solid Tumors

Prasad S. Adusumilli, M.D., FACS, FCCP, Deputy Chief, Translational and Clinical Research, Thoracic Surgery; Associate Attending, Thoracic Surgery; Member, Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center

CAR T-cell therapy for solid tumors is prone to the checkpoint blockade inhibition similar to innate tumor-infiltrating lymphocytes. Strategies to overcome this 'Adaptive Resistance' of infused CAR

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com

T cells can promote their anti-tumor efficacy and functional persistence. Understanding solid tumor type-specific immune microenvironment can guide both cell-intrinsic and extrinsic strategies that can modulate the solid tumor microenvironment in addition to promoting CAR T-cell efficiency.

10:00 Coffee Break

MANUFACTURE AND SCALE-UP

10:30 Challenges and Opportunities for Scale-up of CAR T Cells

*Máire Quigley, Ph.D., Research Investigator I,
Cell and Gene Therapies Unit, Novartis*

The response rates of autologous CAR T cell therapies in early clinical trials give hope that these treatments can be developed and widely distributed to patients with unmet need. To successfully evolve from small scale production to commercial manufacturing, multiple challenges must be overcome. Lessons learned from the process scale up of CD19 CAR T cell production will be discussed.

11:00 Cell Therapy: Quality and Good Manufacturing Practices

*Yeong "Christopher" Choi, Ph.D., Director, TCPF
and Assistant Professor, Oncology, Center for
Immunotherapy, Roswell Park Cancer Institute*

To bring ground breaking new cell therapies into the clinic, a massive amount of infrastructure is needed. One of the key components is a drug manufacturing facility, which is compliant with US FDA GMP regulations. One of the major challenges of operating a cell therapy cGMP facility, is maintaining a robust Quality Management System. Fortunately, there are a number of voluntary accrediting organizations to promote excellence in the laboratory.

11:30 Manufacturing of Collectis' Allogeneic UCART Product Candidates

*Arjan Roozen, Vice President, GMP
Solutions & Manufacturing, Collectis*

This talk will provide an introduction of the concept of Collectis' allogeneic UCART product candidates and our technological platform. It will describe and explain the challenges during the process of bringing allogeneic UCART product candidates from R&D development phase to the GMP manufacturing phase, in order to have CTM (clinical trial material) available for clinical studies, and afterwards to plan commercial manufacturing of Collectis' allogeneic UCART GMP cellular gene therapy products.

12:00 pm Close of Adoptive T Cell Therapy

PRESENT A POSTER AND **SAVE \$50!**

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by **July 29, 2016**.

Reasons you should present your research poster at this conference:

- Your poster will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions
- Receive \$50 off your registration
- Your poster abstract will be published in our conference materials



250 First Avenue
Needham, MA 02494
www.healthtech.com

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

THU-FRI | SEPTEMBER 1-2



Biomarkers for Immuno-Oncology

Predictive Biomarkers and Companion Diagnostics to Guide Cancer Immunotherapy

Recommended Dinner Short Course*

ThinkTank: PD-L1 Assays for Biomarkers and Companion Diagnostics

*Separate registration required, please see [Short Courses](#) for details

THURSDAY, SEPTEMBER 1

7:45 am Registration & Morning Coffee

COMPANION DIAGNOSTICS FOR IMMUNOTHERAPY

8:25 Chairperson's Opening Remarks

Kenneth Emancipator, M.D., Executive Medical Director, Companion Diagnostics, Merck & Co.

8:30 Developing an Immunohistochemistry Test for Programmed Cell Death Ligand 1 (PD-L1) as a Companion Diagnostic for Pembrolizumab

Kenneth Emancipator, M.D., Executive Medical Director, Companion Diagnostics, Merck & Co.

Tumors express PD-L1 to contribute to escape from immunosurveillance. Pembrolizumab blocks this escape mechanism and thus effectively treats a number of cancers. The rapid clinical development of pembrolizumab required rapid development of an immunohistochemistry assay for PD-L1. Merck developed the assay initially to determine whether or not PD-L1 is a predictive biomarker, then to enrich clinical trials, and ultimately partnered with a diagnostics company to develop the assay as a companion diagnostic.

9:00 Diagnostic Strategies for Cancer Immune Therapy Combinations

Andy Williams, Ph.D., Companion Diagnostics Group Leader, Cancer Immune Therapies, Genentech

Current and future diagnostic opportunities for cancer immune therapies will be covered. This will include companion diagnostics and other informative tests.

9:30 Integration of Cancer Immunotherapy into Precision Medicine

Zhen Su, M.D., MBA, Senior Vice President, Global Head of Medical Affairs Oncology, EMD Serono

10:00 Coffee Break with Exhibit and Poster Viewing

BIOMARKERS TO GUIDE IMMUNOTHERAPY

10:45 Regulatory Considerations for Diagnostics to Guide Cancer Immunotherapy

Janaki Veeraghavan, Ph.D., Biologist, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, FDA

11:15 Novel T Cell Biomarkers for Response to PD-1 and PD-1/CTLA4 Immunotherapy

Adil Daud, M.D., Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Immunotherapy with checkpoint inhibitors has revolutionized the treatment of many cancers. However, even with these agents, 40-60% of patients with advanced melanoma, 50-80% of patients with NSCLC, and even higher proportions of patients in other cancers do not respond. While earlier studies had examined PDL-1 as a marker for response, a deeper understanding is now emerging integrating several tumor and host factors; these include tumor neo-antigens and mutational burden, T cell and APC activation as well as host factors such as the presence or absence of certain metastatic locations which can determine success with immunotherapy.

11:45 Immuno-Oncological Biomarkers in Hematological and Solid Tumors

Scott Rodig, M.D., Ph.D., Associate Professor, Pathology, Harvard Medical School; Associate Pathologist, Pathology, Brigham & Women's Hospital

Clinical response to immune checkpoint inhibitors is associated, in part, to tumor-specific expression of the PD-1 ligands (PDLs) PD-L1 and PD-L2. PDLs are upregulated on tumor cells by cell autonomous and microenvironmental mechanisms. I will speak about a genetic basis for PD-L1 and PD-L2 expression found in a subset of hematological malignancies and a subset of solid tumors. The correlations between genetics, tumor phenotype, and patient response to chemotherapy and immune therapy will be discussed.

12:15 pm Multiscalar Systems Modeling to Design Rational Cancer Immunotherapy Combinations

Sponsored by:



Spyro Mousses, Ph.D., President, Systems Imagination, Inc.

This case study will describe the mining and modeling of disparate types of information ranging from WGS data to deep clinical phenotype data including pathological and radiological images. Results identified hidden insights that can be leveraged to design safer and more effective drug combinations for cancer immunotherapy.

12:30 Sponsored Presentation (Opportunity Available)

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Session Break

BIOMARKER DEVELOPMENT FOR PERSONALIZED IMMUNOTHERAPY

2:00 Chairperson's Remarks

Chan Whiting, Ph.D., Director, Immune Monitoring/ Biomarker Development, Aduro Biotech

2:05 Emerging Biomarkers and Novel High-Throughput Technologies for Personalized Cancer Immunotherapy

Jianda Yuan, M.D., Ph.D., Director, Translational Immuno-Oncology Research, Merck Research Labs

There is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. We (SITC Biomarker Task Force Working Group 2 with international experts from academia and industry) assemble to identify and discuss promising technologies for biomarker discovery and validation. We review the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

as high dimensional data analysis platforms that will be pivotal for future biomarker research.

2:35 High-Dimensional Single Cell Analyses in Tumor Tissues

Sacha Gnajic, Ph.D., Associate Professor, Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai

The density and distribution of immune cells at the tumor site can be useful as a prognostic or predictive marker of clinical response in many different cancers. New high-dimensional analysis tools for both fresh and preserved tissues are now available to assess the phenotypic and functional tumor immune microenvironment with unprecedented depth and complexity. These studies are poised to help better define local immunocompetence in individual patients, and correlate it with peripheral immune markers and predicted outcome, to improve patient stratification to immunotherapies or other interventions.

3:05 Sponsored Presentations (Opportunities Available)

3:35 Refreshment Break

4:05 Human Tissue as a Platform for Developing Predictive Biomarkers: A Case Study in PD-L1

Robert Anders, M.D., Ph.D., Associate Professor, Pathology, Johns Hopkins University

Pathologic examination of human tissue has long served as a prognostic biomarker. Increasingly, human tissue is being used to develop predictive biomarkers in the form of immunohistochemistry-based companion or complementary diagnostic tests. However, the evaluation of immunohistochemical studies must be considered in the context of i) tumor type, ii) immune microenvironment, iii) relationship to treatment, and iv) limitations of immunohistochemical staining.

4:35 NanoFACS: Extracellular Vesicle Subset Sorting and Analysis for Personalized Medicine

Jennifer C. Jones, M.D., Ph.D., Assistant Clinical Investigator, Molecular Immunogenetics & Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health

5:05 Biomarkers for Cancer Immunotherapy Using Live-Attenuated *Listeria monocytogenes*

Chan Whiting, Ph.D., Director, Immune Monitoring/Biomarker Development, Aduro Biotech

A live-attenuated double deleted Lm (LADD) immunotherapy induces systemic cytokines, repro-

grams the tumor microenvironment and provides clinical benefit. A description of *Listeria*-based immunotherapy of clinical studies in mesothelioma, pancreatic cancers including comprehensive immune monitoring and biomarker development efforts in these settings will be discussed.

5:05 Dinner Short Course Registration*

*Separate registration required, please see [Short Courses](#) for details

5:35 End of Day

FRIDAY, SEPTEMBER 2

8:00 am Morning Coffee

CLINICAL IMMUNO-ONCOLOGY COMBINATIONS

8:25 Chairperson's Opening Remarks

Jan ter Meulen, M.D., Dr.habil., DTM&H, CSO, Immune Design

8:30 Clinical Immuno-Oncology Combinations

Robert Iannone, M.D., Senior Vice President & Head, Immuno-Oncology, Global Medicines Development, AstraZeneca

9:00 Cancer Immunotherapy and Biomarker Strategies for Combination Studies

Jeffrey Wallin, Ph.D., Group Leader, Early Stage Oncology Biomarker Development, Genentech

The activation of anti-tumor immunity by immune checkpoint blockade has demonstrated efficacy in a variety of cancers. Although durable responses have been observed, combination approaches will be required to extend this benefit beyond a subset of patients. Combinations for cancer immunotherapy involve promotion of one or more steps of the cancer-immunity cycle and biomarkers can provide valuable diagnostic and mechanistic information for cancer immunotherapy clinical trials.

9:30 Cancer Immunotherapy in Combination

Jennifer Mataraza, Ph.D., Senior Investigator, Immune Oncology, Novartis Institutes for BioMedical Research

This presentation will cover: (1) the role of checkpoint inhibitors in the context of a broader immuno-oncology strategy; (2) an outline of the status of the Novartis checkpoint pipeline; (3) approaches to the discovery of novel CPIs and overcoming resistance.

10:00 Coffee Break

10:30 Novel Approaches for Combination Immunotherapy of Cancer: Lessons Learned and Future Opportunities

Jon Wigginton, M.D., CMO & Senior Vice President, Clinical Development, MacroGenics

There has been tremendous progress in the field of cancer immunotherapy as it has moved recently into the mainstream for the treatment of many cancers. A broad range of non-clinical studies, and more recently, powerful new clinical data from studies combining anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) for the treatment of patients with melanoma, have focused considerable attention on the potential promise of combination cancer immunotherapy. This presentation will provide an overview of current progress, lessons learned, and future prospects for the combination immunotherapy of cancer.

11:00 Combined IL-15-Based Cytokine Therapy with PD-1 Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer

John Wrangle, M.D., Assistant Professor, Medicine, Hematology/Oncology, Medical University of South Carolina

11:30 Inducing Local and Systemic Anti-Tumor Responses through *in situ* Vaccination: Synergy of the TLR4 Agonist G100 with Localized Radiation Therapy

Jan ter Meulen, M.D., Dr.habil., DTM&H, CSO, Immune Design

The immunosuppressive tumor microenvironment (TME) is a main obstacle to successful cancer immunotherapy. Intratumoral injection of the TLR4 agonist Glucopyranosyl Lipid A in stable emulsion (G100) induces in a pro-inflammatory state of the TME that promotes local and systemic immune responses and tumor control via CD8 T cells. Focal irradiation of tumors enhances G100-mediated tumor control, especially of non-treated lesions (abscopal effect), and supports clinical development as a combination therapy.

12:00 pm Close of Biomarkers for Immuno-Oncology Conference

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com



250 First Avenue
Needham, MA 02494
www.healthtech.com

THU-FRI | SEPTEMBER 1-2



Clinical Trials for Cancer Immunotherapy

Strategies to Accelerate Immuno-Oncology Clinical Development

Recommended Dinner Short Course*

ThinkTank: PD-L1 Assays for Biomarkers and Companion Diagnostics

*Separate registration required, please see [Short Courses](#) for details

THURSDAY, SEPTEMBER 1

7:45 am Registration & Morning Coffee

COMPANION DIAGNOSTICS FOR IMMUNOTHERAPY

8:25 Chairperson's Opening Remarks

Kenneth Emancipator, M.D., Executive Medical Director, Companion Diagnostics, Merck & Co.

8:30 Developing an Immunohistochemistry Test for Programmed Cell Death Ligand 1 (PD-L1) as a Companion Diagnostic for Pembrolizumab

Kenneth Emancipator, M.D., Executive Medical Director, Companion Diagnostics, Merck & Co.

Tumors express PD-L1 to contribute to escape from immunosurveillance. Pembrolizumab blocks this escape mechanism and thus effectively treats a number of cancers. The rapid clinical development of pembrolizumab required rapid development of an immunohistochemistry assay for PD-L1. Merck developed the assay initially to determine whether or not PD-L1 is a predictive biomarker, then to enrich clinical trials, and ultimately partnered with a diagnostics company to develop the assay as a companion diagnostic.

9:00 Diagnostic Strategies for Cancer Immune Therapy Combinations

Andy Williams, Ph.D., Companion Diagnostics Group Leader, Cancer Immune Therapies, Genentech

Current and future diagnostic opportunities for cancer immune therapies will be covered. This will include companion diagnostics and other informative tests.

9:30 Integration of Cancer Immunotherapy into Precision Medicine

Zhen Su, M.D., MBA, Senior Vice President, Global Head of Medical Affairs Oncology, EMD Serono

10:00 Coffee Break with Exhibit and Poster Viewing

IMMUNO-ONCOLOGY CLINICAL DEVELOPMENT STRATEGIES

10:45 PD-1 Antibody Has the Potential to Be a Broad Spectrum Antineoplastic Therapy

Roy D. Baynes, M.D., Ph.D., Senior Vice President and Head, Global Clinical Development, Merck Research Laboratories

PD-1 antibody blocks ligands PDL-1 and PDL-2 binding to PD-1 receptor, and activates cytotoxic killer cells, revealing innate immunity to cancer. Big data sets evaluating PDL-1 expression and mutational burden were interrogated to accelerate development. This enabled early approvals in malignant melanoma and NSCLC along with a companion diagnostic. More than 20 different responsive cancers have been identified. Precision medicine approaches identify patients for whom monotherapy is most appropriate and those for whom additional therapies should be considered.

11:15 The Combination Conundrum

James E. Wooldridge, M.D., CSO, Immuno-Oncology Clinical Development, Eli Lilly and Company

11:45 Cancer Immunotherapy: Triumphs and Challenges

Joseph Pearlberg, M.D., Ph.D., Senior Medical Director, Infinity Pharmaceuticals

12:15 pm Sponsored Presentations (Opportunities Available)

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Session Break

CLINICAL DEVELOPMENT FOR CHECKPOINT INHIBITORS

2:00 Chairperson's Remarks

Vassiliki Karantza, M.D., Ph.D., Director, Clinical Research Oncology, Merck Research Laboratories

2:05 PD-1 Inhibition by Pembrolizumab for Breast Cancer Treatment

Vassiliki Karantza, M.D., Ph.D., Senior Director, Clinical Research Oncology, Merck Research Laboratories

The PD-1 receptor-ligand pathway is used by tumors to evade immune surveillance. Pembrolizumab is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thus reactivating the immune system to eradicate tumors. Pembrolizumab has shown robust antitumor activity against several advanced malignancies. The safety and efficacy of pembrolizumab in patients with PD-L1-positive advanced breast cancer (triple-negative and ER-positive/HER2-negative) will be discussed.

2:35 The Role of Immune-Checkpoint Therapy in Cancers with Deficient Mismatch Repair

Michael J. Overman, M.D., Associate Professor, Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center

Initial investigations of immune-checkpoint therapy targeting PD1/PDL1 in unselected colorectal cancer (CRC) have demonstrated limited to no activity. However, a subset of CRC, characterized by mismatch deficiency or microsatellite instability (MSI-high), has demonstrated robust early signals of anti-tumor activity with PD1 targeting. It is now clear that MSI-high cancers represent a unique molecular and immunological tumor subset. This talk will discuss the current and ongoing clinical trials investigating immune therapy in this disease subset.

3:05 Sponsored Presentations (Opportunities Available)

3:35 Refreshment Break

4:05 Checkpoint Inhibitors for Gliomas

Michael Lim, M.D., Associate Professor, Neurosurgery, Oncology and Radiation Oncology, Johns Hopkins University School of Medicine

The poor prognosis of patients with glioblastoma mandates new approaches. Checkpoint inhibitors are an exciting class of immune-based strategies that have been shown to improve survival in solid tumors such as melanoma, lung cancers, and renal cell cancers. We will discuss the state of checkpoint inhibitors in glioblastoma. We will specifically

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
Immuno-Oncology
Summit.com

ly focus on the existing preclinical data, current clinical trials, and future combination approaches with checkpoint inhibitors for glioblastoma.

4:35 Clinical Biomarkers of a STAT3 Antisense Oligonucleotide, AZD9150

Patricia McCoon, Ph.D., Principal Scientist, Oncology IMED Translational Science, AstraZeneca Pharmaceuticals

AZD9150 is a therapeutic antisense oligonucleotide targeting STAT3 that has shown clinical safety and efficacy in two Phase I clinical trials. Clinical biomarker analysis demonstrated STAT3 knockdown in immune cells, and additional gene expression changes associated with better response to immune checkpoint blockade. Addition of mouse STAT3 ASO to anti-PDL1 treatment showed benefit in preclinical syngeneic tumor models. Based on these data, Phase Ib/2 clinical trials have been initiated testing AZD9150 + durvalumab.

5:05 Talk Title to be Announced

Patrick Forde, M.D., Assistant Professor, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

5:05 Dinner Short Course Registration*

*Separate registration required, please see [Short Courses](#) for details

5:35 End of Day

FRIDAY, SEPTEMBER 2

8:00 am Morning Coffee

CLINICAL IMMUNO-ONCOLOGY COMBINATIONS

8:25 Chairperson's Opening Remarks

Jan ter Meulen, M.D., Dr.habil., DTM&H, CSO, Immune Design

8:30 Clinical Immuno-Oncology Combinations

Robert Iannone, M.D., Senior Vice President & Head, Immuno-Oncology, Global Medicines Development, AstraZeneca

9:00 Cancer Immunotherapy and Biomarker Strategies for Combination Studies

Jeffrey Wallin, Ph.D., Group Leader, Early Stage Oncology Biomarker Development, Genentech

The activation of anti-tumor immunity by immune checkpoint blockade has demonstrated efficacy in a variety of cancers. Although durable responses have been observed, combination approaches will be required to extend this benefit beyond a subset of patients. Combinations for cancer immunotherapy involve promotion of one or more steps of the cancer-immunity cycle and biomarkers can provide valuable diagnostic and mechanistic information for cancer immunotherapy clinical trials.

9:30 Cancer Immunotherapy in Combination

Jennifer Mataraza, Ph.D., Senior Investigator, Immune Oncology, Novartis Institutes for BioMedical Research
This presentation will cover: (1) the role of checkpoint inhibitors in the context of a broader immuno-oncology strategy; (2) an outline of the status of the Novartis checkpoint pipeline; (3) approaches to the discovery of novel CPIs and overcoming resistance.

10:00 Coffee Break

10:30 Novel Approaches for Combination Immunotherapy of Cancer: Lessons Learned and Future Opportunities

Jon Wigginton, M.D., CMO & Senior Vice President, Clinical Development, MacroGenics

There has been tremendous progress in the field of cancer immunotherapy as it has moved recently into the mainstream for the treatment of many cancers. A broad range of non-clinical studies, and more recently, powerful new clinical data from studies combining anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) for the treatment of patients with melanoma, have focused considerable attention on the potential promise of combination cancer immunotherapy. This presentation will provide an overview of current progress, lessons learned, and future prospects for the combination immunotherapy of cancer.

11:00 Combined IL-15 Based Cytokine Therapy with PD-1 Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer

John Wrangle, M.D., Assistant Professor, Medicine, Hematology/Oncology, Medical University of South Carolina

11:30 Inducing Local and Systemic Anti-Tumor Responses through *in situ* Vaccination: Synergy of the TLR4 Agonist G100 with Localized Radiation Therapy

Jan ter Meulen, M.D., Dr.habil., DTM&H, CSO, Immune Design

The immunosuppressive tumor microenvironment (TME) is a main obstacle to successful cancer immunotherapy. Intratumoral injection of the TLR4 agonist Glucopyranosyl Lipid A in stable emulsion (G100) induces in a pro-inflammatory state of the TME that promotes local and systemic immune responses and tumor control via CD8 T cells. Focal irradiation of tumors enhances G100-mediated tumor control, especially of non-treated lesions (abscopal effect), and supports clinical development as a combination therapy.

12:00 pm Close of Clinical Trials for Cancer Immunotherapy Conference



250 First Avenue
Needham, MA 02494
www.healthtech.com

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
Information

Registration
Information

Click Here to
Register Online!
[Immuno-Oncology
Summit.com](http://Immuno-OncologySummit.com)

Conference Venue and Hotel:

Marriott Long Wharf

296 State Street
Boston, MA 02109
T: 617.227.0800

Reservations:

Go to the travel page of
Immuno-OncologySummit.com.

Discounted Room Rate: \$289 s/d

Discount Cut-off Date:
August 1, 2016



250 First Avenue
Needham, MA 02494
www.healthtech.com

Cover

Conference-
at-a-Glance

Keynotes

Faculty

Short Courses

Sponsor & Exhibit
Opportunities

Training Seminar

Agenda

Hotel & Travel
InformationRegistration
InformationClick Here to
Register Online!
Immuno-Oncology
Summit.com

250 First Avenue
Needham, MA 02494
www.healthtech.com



Immuno-Oncology SUMMIT 2016

SHORT COURSES

	Commercial	Academic, Government, Hospital-affiliated
One short course	\$699	\$399
Two short courses	\$999	\$699

Tuesday, August 30, 6:30-9:00	Thursday, September 1, 6:00-9:00
SC1: Targeting the Cancer Mutanome	SC3: ThinkTank: PD-L1 Assays for Biomarkers and Companion Diagnostics
SC2: Bispecific Antibody Development for Immunotherapy	SC4: Adoptive Therapy With CAR T Cells

CONFERENCE AND TRAINING SEMINAR PACKAGES

PREMIUM PACKAGE (Includes access to all conferences and Training Seminar Monday – Friday. Excludes short courses.)

Early Registration until June 10	\$2,949	\$1,499
Advance Registration until July 29	\$3,099	\$1,699
Registration after July 29	\$3,299	\$1,799

STANDARD PACKAGE (Includes access to 2 conferences and/or Training Seminar. Excludes short courses.)

Early Registration until June 10	\$2,499	\$1,229
Advance Registration until July 29	\$2,649	\$1,349
Registration after July 29	\$2,799	\$1,399

BASIC PACKAGE (Includes access to 1 conference or Training Seminar. Excludes short courses.)

Early Registration until June 10	\$1,599	\$849
Advance Registration until July 29	\$1,799	\$899
Registration after July 29	\$1,949	\$999

Monday – Tuesday	Tuesday (pm) – Wednesday	Thursday – Friday
Immunomodulatory Antibodies	Combination Immunotherapy	Adoptive T Cell Therapy
Oncolytic Virus Immunotherapy	Personalized Immunotherapy	Biomarkers for Immuno-Oncology
Training Seminar: Immunology for Drug Discovery Scientists	Preclinical & Translational Immuno-Oncology	Clinical Trials for Cancer Immunotherapy

CONFERENCE DISCOUNTS

Poster Submission: Poster abstracts are due by July 29, 2016. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. * CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

Alumni Discount: Cambridge Healthtech Institute (CHI) appreciates your past participation at the Immuno-Oncology Summit. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate. Please note: Our records must indicate you were an attendee of the Immuno-Oncology Summit in the past in order to qualify.

Group Discounts are Available! Special rates are available for multiple attendees from the same organization. For more information on group discounts contact Cathy Almquist at 781-972-5547 or calmquist@healthtech.com

If you are unable to attend but would like to purchase the Event Proceedings CD for \$750 (+shipping), please visit Immuno-OncologySummit.com.

Healthtech Publishing

Complimentary news delivered to your inbox

Bio-IT World

News on the data deluge in petascale computing and the tools to deliver individualized medicine.
Bio-ITWorld.com

CLINICAL INFORMATICS NEWS

Insights on the innovation between clinical trial management and delivery of care. ClinicalInformaticsNews.com

DiagnosticsWorld

Emerging Technologies in Diagnostics
DiagnosticsWorldNews.com



Reports designed to keep life science professionals informed of the salient trends in pharma technology, business, clinical development, and therapeutic disease markets
InsightPharmaReports.com
Contact Adriana Randall,
arandall@healthtech.com / +1-781-972-5402



Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit BarnettInternational.com.

ADDITIONAL REGISTRATION DETAILS

Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

To view our Substitutions/Cancellations Policy, go to healthtech.com/regdetails

Video and/or audio recording of any kind is prohibited onsite at all CHI events.

How to Register: Immuno-OncologySummit.com

reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288